Neurotransmitters and Immunity: Molecular Mechanisms, Biological Functions, Diseases, and Potential Therapeutic Targets

Abstract

Traditionally considered to function solely as signaling molecules within the central nervous system (CNS), neurotransmitters are now recognized as key regulators of systemic homeostasis. They modulate interactions among the nervous, immune, and metabolic systems and influence the development of various diseases. This review systematically summarizes the fundamental properties of major neurotransmitters, including their biosynthesis, receptor subtypes, and key signaling pathways, and analyzes their context-dependent roles in cancer, neurodegenerative diseases (NDDs), and inflammatory disorders. A primary focus is the three-dimensional regulatory principle that determines their effects, namely: the receptor type they bind to, cellular microenvironment, and stage of the disease. These factors explain the bidirectional effects of neurotransmitters in disease. This review also evaluates current therapeutic approaches targeting neurotransmitter pathways, ranging from receptor-specific drugs to emerging combination therapies, and discusses challenges in clinical translation, such as off-target effects of nonspecific drugs and variable efficacy across disease types. By linking the fundamental mechanisms of neurotransmitter function to clinical challenges, this review provides a comprehensive framework for exploiting the neurotransmitter–immune axis to develop precise therapeutic strategies aimed at improving outcomes in cancer, NDDs, and inflammatory disorders.

Keywords

cancer / inflammatory disorders / neurodegenerative diseases / neurotransmitters

References

[1] M. A. Cox, C. Bassi, M. E. Saunders, et al., “Beyond Neurotransmission: Acetylcholine in Immunity and Inflammation,” Journal of Internal Medicine 287, no. 2 (2020): 120–133.

[2] N. Liu, S. Sun, P. Wang, et al., “The Mechanism of Secretion and Metabolism of Gut-Derived 5-Hydroxytryptamine,” International Journal of Molecular Sciences 22, no. 15 (2021): 7931.

[3] B. W. Renz, R. Takahashi, T. Tanaka, et al., “β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer,” Cancer Cell 33, no. 1 (2018): 75–90.e77.

[4] S. H. Jiang, L. P. Hu, X. Wang, et al., “Neurotransmitters: Emerging Targets in Cancer,” Oncogene 39, no. 3 (2020): 503–515.

[5] A. A. Rahman, R. Stavely, W. Pan, et al., “Optogenetic Activation of Cholinergic Enteric Neurons Reduces Inflammation in Experimental Colitis,” Cellular and Molecular Gastroenterology and Hepatology 17, no. 6 (2024): 907–921.

[6] R. Gosens, J. Zaagsma, H. Meurs, et al., “Muscarinic Receptor Signaling in the Pathophysiology of Asthma and COPD,” Respiratory Research 7, no. 1 (2006): 73.

[7] C. M. Hernandez, R. Kayed, H. Zheng, et al., “Loss of Alpha7 Nicotinic Receptors Enhances Beta-Amyloid Oligomer Accumulation, Exacerbating Early-Stage Cognitive Decline and Septohippocampal Pathology in a Mouse Model of Alzheimer's Disease,” Journal of Neuroscience 30, no. 7 (2010): 2442–2453.

[8] G. Dziewczapolski, C. M. Glogowski, E. Masliah, et al., “Deletion of the Alpha 7 Nicotinic Acetylcholine Receptor Gene Improves Cognitive Deficits and Synaptic Pathology in a Mouse Model of Alzheimer's Disease,” Journal of Neuroscience 29, no. 27 (2009): 8805–8815.

[9] A. M. Baig, Z. Rana, S. Tariq, et al., “Traced on the Timeline: Discovery of Acetylcholine and the Components of the Human Cholinergic System in a Primitive Unicellular Eukaryote Acanthamoeba Spp,” ACS Chemical Neuroscience 9, no. 3 (2018): 494–504.

[10] E. Reijmen, L. Vannucci, M. De Couck, et al., “Therapeutic Potential of the Vagus Nerve in Cancer,” Immunology Letters 202 (2018): 38–43.

[11] L. Xiao, X. Li, C. Fang, et al., “Neurotransmitters: Promising Immune Modulators in the Tumor Microenvironment,” Frontiers in Immunology 14 (2023): 1118637.

[12] I. K. Wessler and C. J. Kirkpatrick, “Non-Neuronal Acetylcholine Involved in Reproduction in Mammals and Honeybees,” Journal of Neurochemistry 142, no. suppl. 2, (2017): 144–150.

[13] F. Battaglin, P. Jayachandran, C. Strelez, et al., “Neurotransmitter Signaling: A New Frontier in Colorectal Cancer Biology and Treatment,” Oncogene 41, no. 43 (2022): 4769–4778.

[14] H. Zhang, Q. Kong, J. Wang, et al., “Complex Roles of cAMP-PKA-CREB Signaling in Cancer,” Experimental Hematology & Oncology 9, no. 1 (2020): 32.

[15] K. Cheng, P. Zimniak, and J. P. Raufman, “Transactivation of the Epidermal Growth Factor Receptor Mediates Cholinergic Agonist-Induced Proliferation of H508 Human Colon Cancer Cells,” Cancer Research 63, no. 20 (2003): 6744–6750.

[16] K. Cheng, R. Samimi, G. Xie, et al., “Acetylcholine Release by Human Colon Cancer Cells Mediates Autocrine Stimulation of Cell Proliferation,” American Journal of Physiology Gastrointestinal and Liver Physiology 295, no. 3 (2008): G591–G597.

[17] E. R. Spindel, “Cholinergic Targets in Lung Cancer,” Current Pharmaceutical Design 22, no. 14 (2016): 2152–2159.

[18] M. Tolaymat, S. M. Larabee, S. Hu, et al., “The Role of M3 Muscarinic Receptor Ligand-Induced Kinase Signaling in Colon Cancer Progression,” Cancers 11, no. 3 (2019): 308.

[19] G. Lin, L. Sun, R. Wang, et al., “Overexpression of Muscarinic Receptor 3 Promotes Metastasis and Predicts Poor Prognosis in Non-Small-Cell Lung Cancer,” Journal of Thoracic Oncology 9, no. 2 (2014): 170–178.

[20] L. Wang, X. Zhi, Q. Zhang, et al., “Muscarinic Receptor M3 Mediates Cell Proliferation Induced by Acetylcholine and Contributes to Apoptosis in Gastric Cancer,” Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine 37, no. 2 (2016): 2105–2117.

[21] R. Xu, C. Shang, J. Zhao, et al., “Activation of M3 Muscarinic Receptor by Acetylcholine Promotes Non-Small Cell Lung Cancer Cell Proliferation and Invasion via EGFR/PI3K/AKT Pathway,” Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine 36, no. 6 (2015): 4091–4100.

[22] J. Yang, J. Chen, J. He, et al., “Wnt Signaling as Potential Therapeutic Target in Lung Cancer,” Expert Opinion on Therapeutic Targets 20, no. 8 (2016): 999–1015.

[23] C. Zhang, P. Yu, L. Zhu, et al., “Blockade of α7 Nicotinic Acetylcholine Receptors Inhibit Nicotine-Induced Tumor Growth and Vimentin Expression in Non-Small Cell Lung Cancer Through MEK/ERK Signaling Way,” Oncology Reports 38, no. 6 (2017): 3309–3318.

[24] H. Yu, H. Xia, Q. Tang, et al., “Acetylcholine Acts Through M3 Muscarinic Receptor to Activate the EGFR Signaling and Promotes Gastric Cancer Cell Proliferation,” Scientific Reports 7 (2017): 40802.

[25] Y. Hayakawa, K. Sakitani, M. Konishi, et al., “Nerve Growth Factor Promotes Gastric Tumorigenesis Through Aberrant Cholinergic Signaling,” Cancer Cell 31, no. 1 (2017): 21–34.

[26] G. Xie, K. Cheng, J. Shant, et al., “Acetylcholine-Induced Activation of M3 Muscarinic Receptors Stimulates Robust Matrix Metalloproteinase Gene Expression in Human Colon Cancer Cells,” American Journal of Physiology Gastrointestinal and Liver Physiology 296, no. 4 (2009): G755–G763.

[27] S. Bai, W. Wen, X. Hou, et al., “Inhibitory Effect of Sinomenine on Lung Cancer Cells via Negative Regulation of α7 Nicotinic Acetylcholine Receptor,” Journal of Leukocyte Biology 109, no. 4 (2021): 843–852.

[28] A. R. Iskandar, B. Miao, X. Li, et al., “β-Cryptoxanthin Reduced Lung Tumor Multiplicity and Inhibited Lung Cancer Cell Motility by Downregulating Nicotinic Acetylcholine Receptor α7 Signaling,” Cancer Prevention Research (Philadelphia, Pa) 9, no. 11 (2016): 875–886.

[29] J. Qian, Y. Liu, Z. Sun, et al., “Identification of Nicotinic Acetylcholine Receptor Subunits in Different Lung Cancer Cell Lines and the Inhibitory Effect of Alpha-Conotoxin TxID on Lung Cancer Cell Growth,” European Journal of Pharmacology 865 (2019): 172674.

[30] H. Yu, H. Xia, Q. Tang, et al., “Acetylcholine Acts Through M3 Muscarinic Receptor to Activate the EGFR Signaling and Promotes Gastric Cancer Cell Proliferation,” Scientific Reports 7 (2017): 40802.

[31] N. A. Hering, V. Liu, R. Kim, et al., “Blockage of Cholinergic Signaling via Muscarinic Acetylcholine Receptor 3 Inhibits Tumor Growth in Human Colorectal Adenocarcinoma,” Cancers 13, no. 13 (2021): 3220.

[32] L. Wang, J. Xu, Y. Xia, et al., “Muscarinic Acetylcholine Receptor 3 Mediates Vagus Nerve-Induced Gastric Cancer,” Oncogenesis 7, no. 11 (2018): 88.

[33] L. Wang, X. Zhi, Q. Zhang, et al., “Muscarinic Receptor M3 Mediates Cell Proliferation Induced by Acetylcholine and Contributes to Apoptosis in Gastric Cancer,” Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine 37, no. 2 (2016): 2105–2117.

[34] X. Bu, A. Zhang, Z. Chen, et al., “Migration of Gastric Cancer Is Suppressed by Recombinant Newcastle Disease Virus (rL-RVG) via Regulating α7-Nicotinic Acetylcholine Receptors/ERK- EMT,” BMC Cancer 19, no. 1 (2019): 976.

[35] S. Ochirbat, T. Kan, C. Hsu, et al., “The Angiogenic Role of the Alpha 9-Nicotinic Acetylcholine Receptor in Triple-Negative Breast Cancers,” Angiogenesis 27, no. 4 (2024): 827–843.

[36] C. M. Benning and N. Kyprianou, “Quinazoline-Derived Alpha1-Adrenoceptor Antagonists Induce Prostate Cancer Cell Apoptosis via an Alpha1-Adrenoceptor-Independent Action,” Cancer Research 62, no. 2 (2002): 597–602.

[37] A. M. Harris, B. W. Warner, J. M. Wilson, et al., “Effect of Alpha1-Adrenoceptor Antagonist Exposure on Prostate Cancer Incidence: An Observational Cohort Study,” Journal of Urology 178, no. 5 (2007): 2176–2180.

[38] C. Pérez Piñero, A. Bruzzone, M. G. Sarappa, et al., “Involvement of α2- and β2-Adrenoceptors on Breast Cancer Cell Proliferation and Tumour Growth Regulation,” British Journal of Pharmacology 166, no. 2 (2012): 721–736.

[39] Y. Lu, D. Cheng, J. Pang, et al., “Chronic Stress Promotes Gastric Cancer Progression via the Adrenoceptor Beta 2/PlexinA1 Pathway,” Cell Stress & Chaperones 29, no. 1 (2024): 201–215.

[40] M. Dal Monte, M. Calvani, M. Cammalleri, et al., “β-Adrenoceptors as Drug Targets in Melanoma: Novel Preclinical Evidence for a Role of β3-Adrenoceptors,” British Journal of Pharmacology 176, no. 14 (2019): 2496–2508.

[41] G. Bruno, F. Cencetti, A. Pini, et al., “β3-Adrenoreceptor Blockade Reduces Tumor Growth and Increases Neuronal Differentiation in Neuroblastoma via SK2/S1P2 Modulation,” Oncogene 39, no. 2 (2020): 368–384.

[42] C. E. Grant, A. L. Flis, and B. M. Ryan, “Understanding the Role of Dopamine in Cancer: Past, Present and Future,” Carcinogenesis 43, no. 6 (2022): 517–527.

[43] D. C. Borcherding, W. Tong, E. R. Hugo, et al., “Expression and Therapeutic Targeting of Dopamine Receptor-1 (D1R) in Breast Cancer,” Oncogene 35, no. 24 (2016): 3103–3113.

[44] Y. Yan, J. Pan, Y. Chen, et al., “Increased Dopamine and Its Receptor Dopamine Receptor D1 Promote Tumor Growth in Human Hepatocellular Carcinoma,” Cancer Communications (London, England) 40, no. 12 (2020): 694–710.

[45] K. Yang, R. Xu, and W. Le, “Dopamine Receptor D1 Agonist Inhibits Glioblastoma via Calpain‑Mediated ER Stress and Mitochondrial Dysfunction,” Oncology Reports 45, no. 5 (2021): 74.

[46] M. Moreno-Smith, S. J. Lee, C. Lu, et al., “Biologic Effects of Dopamine on Tumor Vasculature in Ovarian Carcinoma,” Neoplasia (New York, NY) 15, no. 5 (2013): 502–510.

[47] K. Minami, S. Liu, Y. Liu, et al., “Inhibitory Effects of Dopamine Receptor D1 Agonist on Mammary Tumor and Bone Metastasis,” Scientific Reports 7 (2017): 45686.

[48] S. J. Sim, J. Jang, J. Choi, et al., “Domperidone, a Dopamine Receptor D2 Antagonist, Induces Apoptosis by Inhibiting the ERK/STAT3-Mediated Pathway in Human Colon Cancer HCT116 Cells,” Biomolecules & Therapeutics 32, no. 5 (2024): 568–576.

[49] H. Jeon, Y. T. Oh, Y. J. Shin, et al., “Dopamine Receptor D2 Regulates Glioblastoma Survival and Death Through MET and Death Receptor 4/5,” Neoplasia (New York, NY) 39, (2023): 100894.

[50] C. L. B. Kline, M. D. Ralff, A. R. Lulla, et al., “Role of Dopamine Receptors in the Anticancer Activity of ONC201,” Neoplasia (New York, NY) 20, no. 1 (2018): 80–91.

[51] P. Jandaghi, H. S. Najafabadi, A. S. Bauer, et al., “Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice,” Gastroenterology 151, no. 6 (2016): 1218–1231.

[52] S. Ganguly, B. Basu, S. Shome, et al., “Dopamine, by Acting Through Its D2 Receptor, Inhibits Insulin-Like Growth Factor-I (IGF-I)-Induced Gastric Cancer Cell Proliferation via Up-Regulation of Krüppel-Like Factor 4 Through Down-Regulation of IGF-IR and AKT Phosphorylation,” American Journal of Pathology 177, no. 6 (2010): 2701–2707.

[53] S. Roy, K. Lu, M. K. Nayak, et al., “Activation of D2 Dopamine Receptors in CD133+ve Cancer Stem Cells in Non-Small Cell Lung Carcinoma Inhibits Proliferation, Clonogenic Ability, and Invasiveness of These Cells,” Journal of Biological Chemistry 292, no. 2 (2017): 435–445.

[54] J. Li, Q. Yao, J. Xue, et al., “Dopamine D2 Receptor Antagonist Sulpiride Enhances Dexamethasone Responses in the Treatment of Drug-Resistant and Metastatic Breast Cancer,” Acta Pharmacologica Sinica 38, no. 9 (2017): 1282–1296.

[55] T. Yin, S. He, G. Shen, et al., “Dopamine Receptor Antagonist Thioridazine Inhibits Tumor Growth in a Murine Breast Cancer Model,” Molecular Medicine Reports 12, no. 3 (2015): 4103–4108.

[56] M. Lu, J. Li, Z. Luo, et al., “Roles of Dopamine Receptors and Their Antagonist Thioridazine in Hepatoma Metastasis,” OncoTargets and Therapy 8 (2015): 1543–1552.

[57] M. Yong, T. Yu, S. Tian, et al., “DR2 Blocker Thioridazine: A Promising Drug for Ovarian Cancer Therapy,” Oncology Letters 14, no. 6 (2017): 8171–8177.

[58] A. Pulkoski-Gross, J. Li, C. Zheng, et al., “Repurposing the Antipsychotic Trifluoperazine as an Antimetastasis Agent,” Molecular Pharmacology 87, no. 3 (2015): 501–512.

[59] T. Pinheiro, M. Otrocka, B. Seashore-Ludlow, et al., “Reprint of: A Chemical Screen Identifies Trifluoperazine as an Inhibitor of Glioblastoma Growth,” Biochemical and Biophysical Research Communications 499, no. 2 (2018): 136–142.

[60] C. Yeh, A. T. H. Wu, P. M. H. Chang, et al., “Trifluoperazine, an Antipsychotic Agent, Inhibits Cancer Stem Cell Growth and Overcomes Drug Resistance of Lung Cancer,” American Journal of Respiratory and Critical Care Medicine 186, no. 11 (2012): 1180–1188.

[61] S. Dolma, H. J. Selvadurai, X. Lan, et al., “Inhibition of Dopamine Receptor D4 Impedes Autophagic Flux, Proliferation, and Survival of Glioblastoma Stem Cells,” Cancer Cell 29, no. 6 (2016): 859–873.

[62] N. Dizeyi, A. Bjartell, E. Nilsson, et al., “Expression of Serotonin Receptors and Role of Serotonin in Human Prostate Cancer Tissue and Cell Lines,” Prostate 59, no. 3 (2004): 328–336.

[63] X. Jin, H. Li, B. Li, et al., “Knockdown and Inhibition of Hydroxytryptamine Receptor 1D Suppress Proliferation and Migration of Gastric Cancer Cells,” Biochemical and Biophysical Research Communications 620 (2022): 143–149.

[64] T. Li, L. Wei, X. Zhang, et al., “Serotonin Receptor HTR2B Facilitates Colorectal Cancer Metastasis via CREB1-ZEB1 Axis-Mediated Epithelial-Mesenchymal Transition,” Molecular Cancer Research: MCR 22, no. 6 (2024): 538–554.

[65] S. H. Jiang, J. Li, F. Y. Dong, et al., “Increased Serotonin Signaling Contributes to the Warburg Effect in Pancreatic Tumor Cells Under Metabolic Stress and Promotes Growth of Pancreatic Tumors in Mice,” Gastroenterology 153, no. 1 (2017): 277–291.e219.

[66] I. Cinar, B. Sirin, Z. Halici, et al., “5-HT7 Receptors as a New Target for Prostate Cancer Physiopathology and Treatment: An Experimental Study on PC-3 Cells and FFPE Tissues,” Naunyn-Schmiedebergs Archives of Pharmacology 394, no. 6 (2021): 1205–1213.

[67] H. Yu, T. Qu, J. Yang, et al., “Serotonin Acts Through YAP to Promote Cell Proliferation: Mechanism and Implication in Colorectal Cancer Progression,” Cell Communication and Signaling 21, no. 1 (2023): 75.

[68] G. Lv, T. Wang, H. Zhu, et al., “Vortioxetine Induces Apoptosis and Autophagy of Gastric Cancer AGS Cells via the PI3K/AKT Pathway,” FEBS Open Bio 10, no. 10 (2020): 2157–2165.

[69] M. G. Cattaneo, A. Codignola, L. M. Vicentini, et al., “Nicotine Stimulates a Serotonergic Autocrine Loop in Human Small-Cell Lung Carcinoma,” Cancer Research 53, no. 22 (1993): 5566–5568.

[70] P. Fernández-Nogueira, A. Noguera-Castells, G. Fuster, et al., “Histamine Receptor 1 Inhibition Enhances Antitumor Therapeutic Responses Through Extracellular Signal-Regulated Kinase (ERK) Activation in Breast Cancer,” Cancer Letters 424 (2018): 70–83.

[71] N. Lampiasi, A. Azzolina, G. Montalto, et al., “Histamine and Spontaneously Released Mast Cell Granules Affect the Cell Growth of Human Hepatocellular Carcinoma Cells,” Experimental & Molecular Medicine 39, no. 3 (2007): 284–294.

[72] Y. Zhao, J. Jia, J. Zhang, et al., “Inhibition of Histamine Receptor H3 Suppresses the Growth and Metastasis of Human Non-Small Cell Lung Cancer Cells via Inhibiting PI3K/Akt/mTOR and MEK/ERK Signaling Pathways and Blocking EMT,” Acta Pharmacologica Sinica 42, no. 8 (2021): 1288–1297.

[73] D. Yu, J. Zhao, Y. Wang, et al., “Upregulated Histamine Receptor H3 Promotes Tumor Growth and Metastasis in Hepatocellular Carcinoma,” Oncology Reports 41, no. 6 (2019): 3347–3354.

[74] J. Chen and X. Hu, “Inhibition of Histamine Receptor H3R Suppresses Prostate Cancer Growth, Invasion and Increases Apoptosis via the AR Pathway,” Oncology Letters 16, no. 4 (2018): 4921–4928.

[75] S. A. Watson, L. J. Wilkinson, J. F. Robertson, et al., “Effect of Histamine on the Growth of Human Gastrointestinal Tumours: Reversal by Cimetidine,” Gut 34, no. 8 (1993): 1091–1096.

[76] M. Abdul and N. Hoosein, “N-Methyl-D-Aspartate Receptor in Human Prostate Cancer,” Journal of Membrane Biology 205, no. 3 (2005): 125–128.

[77] K. Watanabe, T. Kanno, T. Oshima, et al., “The NMDA Receptor NR2A Subunit Regulates Proliferation of MKN45 Human Gastric Cancer Cells,” Biochemical and Biophysical Research Communications 367, no. 2 (2008): 487–490.

[78] W. G. North, G. Gao, A. Jensen, et al., “NMDA Receptors Are Expressed by Small-Cell Lung Cancer and Are Potential Targets for Effective Treatment,” Clinical Pharmacology: Advances and Applications 2 (2010): 31–40.

[79] W. G. North, G. Gao, V. A. Memoli, et al., “Breast Cancer Expresses Functional NMDA Receptors,” Breast Cancer Research and Treatment 122, no. 2 (2010): 307–314.

[80] Z. Song, C. He, J. Liu, et al., “Blocking Glutamate-Mediated Signalling Inhibits Human Melanoma Growth and Migration,” Experimental Dermatology 21, no. 12 (2012): 926–931.

[81] S. Gallo, A. Vitacolonna, P. Comoglio, et al., “MET Oncogene Controls Invasive Growth by Coupling with NMDA Receptor,” Cancers 14, no. 18 (2022): 4408.

[82] A. Müller-Längle, H. Lutz, S. Hehlgans, et al., “NMDA Receptor-Mediated Signaling Pathways Enhance Radiation Resistance, Survival and Migration in Glioblastoma Cells-A Potential Target for Adjuvant Radiotherapy,” Cancers 11, no. 4 (2019): 503.

[83] H. S. Haas, R. Pfragner, V. Siegl, et al., “The Non-Competitive Metabotropic Glutamate Receptor-1 Antagonist CPCCOEt Inhibits the In Vitro Growth of Human Melanoma,” Oncology Reports 17, no. 6 (2007): 1399–1404.

[84] H. Xia, Y. Zhao, C. Yu, et al., “Inhibition of Metabotropic Glutamate Receptor 1 Suppresses Tumor Growth and Angiogenesis in Experimental Non-Small Cell Lung Cancer,” European Journal of Pharmacology 783 (2016): 103–111.

[85] C. L. Speyer, M. A. Nassar, A. H. Hachem, et al., “Riluzole Mediates Anti-Tumor Properties in Breast Cancer Cells Independent of Metabotropic Glutamate Receptor-1,” Breast Cancer Research and Treatment 157, no. 2 (2016): 217–228.

[86] Z. Zhang, Y. Liu, K. Wang, et al., “Activation of Type 4 Metabotropic Glutamate Receptor Promotes Cell Apoptosis and Inhibits Proliferation in Bladder Cancer,” Journal of Cellular Physiology 234, no. 3 (2019): 2741–2755.

[87] B. Liu, S. Zhao, C. Qi, et al., “Inhibition of Metabotropic Glutamate Receptor 5 Facilitates Hypoxia-Induced Glioma Cell Death,” Brain Research 1704 (2019): 241–248.

[88] Y. Miao, Y. Zhang, H. Wan, et al., “GABA-Receptor Agonist, Propofol Inhibits Invasion of Colon Carcinoma Cells,” Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie 64, no. 9 (2010): 583–588.

[89] T. Wang, W. Huang, and F. Chen, “Baclofen, a GABAB Receptor Agonist, Inhibits Human Hepatocellular Carcinoma Cell Growth In Vitro and In Vivo,” Life Sciences 82, no. 9–10 (2008): 536–541.

[90] M. Muñoz, M. Rosso, A. Pérez, et al., “The NK1 Receptor Is Involved in the Antitumoural Action of L-733,060 and in the Mitogenic Action of Substance P on Neuroblastoma and Glioma Cell Lines,” Neuropeptides 39, no. 4 (2005): 427–432.

[91] M. Muñoz, A. Pérez, M. Rosso, et al., “Antitumoral Action of the Neurokinin-1 Receptor Antagonist L-733 060 on Human Melanoma Cell Lines,” Melanoma Research 14, no. 3 (2004): 183–188.

[92] M. Rosso, M. J. Robles-Frías, R. Coveñas, et al., “The NK-1 Receptor Is Expressed in Human Primary Gastric and Colon Adenocarcinomas and Is Involved in the Antitumor Action of L-733,060 and the Mitogenic Action of Substance P on Human Gastrointestinal Cancer Cell Lines,” Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine 29, no. 4 (2008): 245–254.

[93] M. Muñoz, A. Pérez, R. Coveñas, et al., “Antitumoural Action of L-733,060 on Neuroblastoma and Glioma Cell Lines,” Archives Italiennes de Biologie 142, no. 2 (2004): 105–112.

[94] P. Tie, J. Cheng, M. X. Xue, et al., “SLC18A3 Promoted Renal Cancer Development Through Acetylcholine/cAMP Signaling,” American Journal of Cancer Research 12, no. 9 (2022): 4279–4289.

[95] T. Yang, W. He, F. Cui, et al., “MACC1 Mediates Acetylcholine-Induced Invasion and Migration by Human Gastric Cancer Cells,” Oncotarget 7, no. 14 (2016): 18085–18094.

[96] H. Nie, Q. Cao, L. Zhu, et al., “Acetylcholine Acts on Androgen Receptor to Promote the Migration and Invasion but Inhibit the Apoptosis of Human Hepatocarcinoma,” PLoS ONE 8, no. 4 (2013): e61678.

[97] Y. Jiao, G. Kang, P. Pan, et al., “Acetylcholine Promotes Chronic Stress-Induced Lung Adenocarcinoma Progression via α5-nAChR/FHIT Pathway,” Cellular and Molecular Life Sciences: CMLS 80, no. 5 (2023): 119.

[98] D. Manfredelli, T. Armeni, L. de Bari, et al., “Acetylcholine Sustains LNCaP Prostate Cancer Cell Migration, Invasion and Proliferation Through Glyoxalase 1/MG-H1 Axis with the Involvement of Osteopontin,” International Journal of Molecular Sciences 26, no. 9 (2025): 4107.

[99] K. Kawashima and T. Fujii, “Expression of Non-Neuronal Acetylcholine in Lymphocytes and Its Contribution to the Regulation of Immune Function,” Frontiers in Bioscience 9 (2004): 2063–2085.

[100] K. Kawashima and T. Fujii, “Basic and Clinical Aspects of Non-Neuronal Acetylcholine: Overview of Non-Neuronal Cholinergic Systems and Their Biological Significance,” Journal of Pharmacological Sciences 106, no. 2 (2008): 167–173.

[101] T. Fujii, M. Mashimo, Y. Moriwaki, et al., “Physiological Functions of the Cholinergic System in Immune Cells,” Journal of Pharmacological Sciences 134, no. 1 (2017): 1–21.

[102] A. I. Chernyavsky, J. Arredondo, M. Skok, et al., “Auto/Paracrine Control of Inflammatory Cytokines by Acetylcholine in Macrophage-Like U937 Cells Through Nicotinic Receptors,” International Immunopharmacology 10, no. 3 (2010): 308–315.

[103] M. Yang, L. Tao, Y. Jiang, et al., “Perineural Invasion Reprograms the Immune Microenvironment Through Cholinergic Signaling in Pancreatic Ductal Adenocarcinoma,” Cancer Research 80, no. 10 (2020): 1991–2003.

[104] M. Asahina, T. Suhara, H. Shinotoh, et al., “Brain Muscarinic Receptors in Progressive Supranuclear Palsy and Parkinson's Disease: A Positron Emission Tomographic Study,” Journal of Neurology, Neurosurgery, and Psychiatry 65, no. 2 (1998): 155–163.

[105] D. Dencker, M. Thomsen, G. Wörtwein, et al., “Muscarinic Acetylcholine Receptor Subtypes as Potential Drug Targets for the Treatment of Schizophrenia, Drug Abuse and Parkinson's Disease,” ACS Chemical Neuroscience 3, no. 2 (2012): 80–89.

[106] P. Calabresi, D. Centonze, and G. Bernardi, “Cellular Factors Controlling Neuronal Vulnerability in the Brain: A Lesson From the Striatum,” Neurology 55, no. 9 (2000): 1249–1255.

[107] J. N. Cremer, K. Amunts, J. Graw, et al., “Neurotransmitter Receptor Density Changes in Pitx3ak Mice—A Model Relevant to Parkinson's Disease,” Neuroscience 285 (2015): 11–23.

[108] L. Shan, O. Diaz, Y. Zhang, et al., “L-DOPA Induced Dyskinesias in Parkinsonian Mice: Disease Severity or L-DOPA History,” Brain Research 1618 (2015): 261–269.

[109] B. Xue, L. Mao, D. Jin, et al., “Regulation of Synaptic MAPK/ERK Phosphorylation in the Rat Striatum and Medial Prefrontal Cortex by Dopamine and Muscarinic Acetylcholine Receptors,” Journal of Neuroscience Research 93, no. 10 (2015): 1592–1599.

[110] J. D. Salamone, M. Correa, B. B. Carlson, et al., “Neostriatal Muscarinic Receptor Subtypes Involved in the Generation of Tremulous Jaw Movements in Rodents Implications for Cholinergic Involvement in Parkinsonism,” Life Sciences 68, no. 22–23 (2001): 2579–2584.

[111] X. Lin, Q. Li, M. Pu, et al., “Significance of Nicotine and Nicotinic Acetylcholine Receptors in Parkinson's Disease,” Frontiers in Aging Neuroscience 17 (2025): 1535310.

[112] H. J. Park, P. H. Lee, Y. W. Ahn, et al., “Neuroprotective Effect of Nicotine on Dopaminergic Neurons by Anti-Inflammatory Action,” European Journal of Neuroscience 26, no. 1 (2007): 79–89.

[113] I. U. Isaias, J. Spiegel, J. Brumberg, et al., “Nicotinic Acetylcholine Receptor Density in Cognitively Intact Subjects at an Early Stage of Parkinson's Disease,” Frontiers in Aging Neuroscience 6 (2014): 213.

[114] D. J. Surmeier, J. Ding, M. Day, et al., “D1 and D2 Dopamine-Receptor Modulation of Striatal Glutamatergic Signaling in Striatal Medium Spiny Neurons,” Trends in Neurosciences 30, no. 5 (2007): 228–235.

[115] S. M. Nicola, J. Surmeier, and R. C. Malenka, “Dopaminergic Modulation of Neuronal Excitability in the Striatum and Nucleus Accumbens,” Annual Review of Neuroscience 23 (2000): 185–215.

[116] G. Rizzi and K. R. Tan, “Dopamine and Acetylcholine, a Circuit Point of View in Parkinson's Disease,” Frontiers in Neural Circuits 11 (2017): 110.

[117] R. Schliebs and T. Arendt, “The Significance of the Cholinergic System in the Brain During Aging and in Alzheimer's Disease,” Journal of Neural Transmission (Vienna, Austria: 1996) 113, no. 11 (2006): 1625–1644.

[118] A. S. Berry and T. M. Harrison, “New Perspectives on the Basal Forebrain Cholinergic System in Alzheimer's Disease,” Neuroscience and Biobehavioral Reviews 150 (2023): 105192.

[119] A. Majdi, S. Sadigh-Eteghad, S. Rahigh Aghsan, et al., “Amyloid-β, Tau, and the Cholinergic System in Alzheimer's Disease: Seeking Direction in a Tangle of Clues,” Reviews in the Neurosciences 31, no. 4 (2020): 391–413.

[120] F. J. Barrantes, V. Borroni, and S. Vallés, “Neuronal Nicotinic Acetylcholine Receptor-Cholesterol Crosstalk in Alzheimer's Disease,” FEBS Letters 584, no. 9 (2010): 1856–1863.

[121] R. Medeiros, M. Kitazawa, A. Caccamo, et al., “Loss of Muscarinic M1 Receptor Exacerbates Alzheimer's Disease-Like Pathology and Cognitive Decline,” American Journal of Pathology 179, no. 2 (2011): 980–991.

[122] S. W. Y. Tsang, M. K. P. Lai, S. Kirvell, et al., “Impaired Coupling of Muscarinic M1 Receptors to G-Proteins in the Neocortex Is Associated With Severity of Dementia in Alzheimer's Disease,” Neurobiology of Aging 27, no. 9 (2006): 1216–1223.

[123] B. Poulin, A. Butcher, P. McWilliams, et al., “The M3-Muscarinic Receptor Regulates Learning and Memory in a Receptor Phosphorylation/Arrestin-Dependent Manner,” Proceedings of the National Academy of Sciences of the United States of America 107, no. 20 (2010): 9440–9445.

[124] D. Paterson and A. Nordberg, “Neuronal Nicotinic Receptors in the Human Brain,” Progress in Neurobiology 61, no. 1 (2000): 75–111.

[125] M. N. Sabbagh, F. Shah, R. T. Reid, et al., “Pathologic and Nicotinic Receptor Binding Differences Between Mild Cognitive Impairment, Alzheimer Disease, and Normal Aging,” Archives of Neurology 63, no. 12 (2006): 1771–1776.

[126] O. Sabri, K. Kendziorra, H. Wolf, et al., “Acetylcholine Receptors in Dementia and Mild Cognitive Impairment,” European Journal of Nuclear Medicine and Molecular Imaging 35, no. suppl. 1 (2008): S30–S45.

[127] E. M. Mitsis, K. M. Reech, F. Bois, et al., “123I-5-IA-85380 SPECT Imaging of Nicotinic Receptors in Alzheimer Disease and Mild Cognitive Impairment,” Journal of Nuclear Medicine 50, no. 9 (2009): 1455–1463.

[128] J. R. Ellis, V. L. Villemagne, P. J. Nathan, et al., “Relationship Between Nicotinic Receptors and Cognitive Function in Early Alzheimer's Disease: A 2-[18F]Fluoro-A-85380 PET Study,” Neurobiology of Learning and Memory 90, no. 2 (2008): 404–412.

[129] J. W. Young, N. Crawford, J. S. Kelly, et al., “Impaired Attention Is Central to the Cognitive Deficits Observed in Alpha 7 Deficient Mice,” European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology 17, no. 2 (2007): 145–155.

[130] G. V. De Ferrari, M. A. Canales, I. Shin, et al., “A Structural Motif of Acetylcholinesterase That Promotes Amyloid Beta-Peptide Fibril Formation,” Biochemistry 40, no. 35 (2001): 10447–10457.

[131] P. Raina, P. Santaguida, A. Ismaila, et al., “Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline,” Annals of Internal Medicine 148, no. 5 (2008): 379–397.

[132] H. Li, M. C. Pham, J. Teng, et al., “Autoimmune Mechanisms Elucidated Through Muscle Acetylcholine Receptor Structures,” Cell 188, no. 9 (2025): 2390–2406.e20.

[133] D. B. Drachman, C. W. Angus, R. N. Adams, et al., “Myasthenic Antibodies Cross-Link Acetylcholine Receptors to Accelerate Degradation,” New England Journal of Medicine 298, no. 20 (1978): 1116–1122.

[134] L. Dresser, R. Wlodarski, K. Rezania, et al., “Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations,” Journal of Clinical Medicine 10, no. 11 (2021): 2235.

[135] J. T. Guptill, D. B. Sanders, and A. Evoli, “Anti-MuSK Antibody Myasthenia Gravis: Clinical Findings and Response to Treatment in Two Large Cohorts,” Muscle & Nerve 44, no. 1 (2011): 36–40.

[136] F. Deymeer, “Myasthenia Gravis: MuSK MG, Late-Onset MG and Ocular MG,” Acta Myologica: Myopathies and Cardiomyopathies: Official Journal of the Mediterranean Society of Myology 39, no. 4 (2020): 345–352.

[137] M. G. Huijbers, D. L. Vergoossen, Y. E. Fillié-Grijpma, et al., “MuSK Myasthenia Gravis Monoclonal Antibodies: Valency Dictates Pathogenicity,” Neurology(R) Neuroimmunology & Neuroinflammation 6, no. 3 (2019): e547.

[138] H. M. Al-Kuraishy, G. M. Sulaiman, M. S. Jabir, et al., “Defective Autophagy and Autophagy Activators in Myasthenia Gravis: A Rare Entity and Unusual Scenario,” Autophagy 20, no. 7 (2024): 1473–1482.

[139] A. Koarai and M. Ichinose, “Possible Involvement of Acetylcholine-Mediated Inflammation in Airway Diseases,” Allergology International: Official Journal of the Japanese Society of Allergology 67, no. 4 (2018): 460–466.

[140] C. R. Gwilt, L. E. Donnelly, and D. F. Rogers, “The Non-Neuronal Cholinergic System in the Airways: An Unappreciated Regulatory Role in Pulmonary Inflammation?” Pharmacology & Therapeutics 115, no. 2 (2007): 208–222.

[141] S. Quirce, J. Domínguez-Ortega, and P. Barranco, “Anticholinergics for Treatment of Asthma,” Journal of Investigational Allergology & Clinical Immunology 25, no. 2 (2015): 84–93.

[142] K. S. Buels and A. D. Fryer, “Muscarinic Receptor Antagonists: Effects on Pulmonary Function,” Handbook of Experimental Pharmacology 208, (2012): 317–341.

[143] P. J. Barnes, “Muscarinic Receptor Subtypes in Airways,” Life Sciences 52, no. 5–6 (1993): 521–527.

[144] L. E. M. Kistemaker and R. Gosens, “Acetylcholine Beyond Bronchoconstriction: Roles in Inflammation and Remodeling,” Trends in Pharmacological Sciences 36, no. 3 (2015): 164–171.

[145] R. Gosens and N. Gross, “The Mode of Action of Anticholinergics in Asthma,” European Respiratory Journal 52, no. 4 (2018): 1701247.

[146] L. E. M. Kistemaker, T. A. Oenema, H. Meurs, et al., “Regulation of Airway Inflammation and Remodeling by Muscarinic Receptors: Perspectives on Anticholinergic Therapy in Asthma and COPD,” Life Sciences 91, no. 21–22 (2012): 1126–1133.

[147] L. Rueda Ruzafa, J. L. Cedillo, and A. J. Hone, “Nicotinic Acetylcholine Receptor Involvement in Inflammatory Bowel Disease and Interactions With Gut Microbiota,” International Journal of Environmental Research and Public Health 18, no. 3 (2021): 1189.

[148] B. Ahluwalia, L. Moraes, M. K. Magnusson, et al., “Immunopathogenesis of Inflammatory Bowel Disease and Mechanisms of Biological Therapies,” Scandinavian Journal of Gastroenterology 53, no. 4 (2018): 379–389.

[149] A. Kelles, J. Janssens, and J. Tack, “IL-1Beta and IL-6 Excite Neurones and Suppress Cholinergic Neurotransmission in the Myenteric Plexus of the Guinea Pig,” Neurogastroenterology and Motility 12, no. 6 (2000): 531–538.

[150] M. Rosas-Ballina, P. S. Olofsson, M. Ochani, et al., “Acetylcholine-Synthesizing T Cells Relay Neural Signals in a Vagus Nerve Circuit,” Science (New York, NY) 334, no. 6052 (2011): 98–101.

[151] J. Arredondo, A. I. Chernyavsky, D. L. Jolkovsky, et al., “Receptor-Mediated Tobacco Toxicity: Cooperation of the Ras/Raf-1/MEK1/ERK and JAK-2/STAT-3 Pathways Downstream of Alpha7 Nicotinic Receptor in Oral Keratinocytes,” FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 20, no. 12 (2006): 2093–2101.

[152] W. J. de Jonge, E. P. van der Zanden, F. O. The, et al., “Stimulation of the Vagus Nerve Attenuates Macrophage Activation by Activating the Jak2-STAT3 Signaling Pathway,” Nature Immunology 6, no. 8 (2005): 844–851.

[153] E. Tyagi, R. Agrawal, C. Nath, et al., “Cholinergic Protection via Alpha7 Nicotinic Acetylcholine Receptors and PI3K-Akt pathway in LPS-Induced Neuroinflammation,” Neurochemistry International 56, no. 1 (2010): 135–142.

[154] T. Kim, S. Kim, and S. Lee, “Stimulation of the α7 Nicotinic Acetylcholine Receptor Protects Against Sepsis by Inhibiting Toll-Like Receptor via Phosphoinositide 3-Kinase Activation,” Journal of Infectious Diseases 209, no. 10 (2014): 1668–1677.

[155] Y. Tasaka, D. Yasunaga, T. Kiyoi, et al., “Involvement of Stimulation of α7 Nicotinic Acetylcholine Receptors in the Suppressive Effect of Tropisetron on Dextran Sulfate Sodium-Induced Colitis in Mice,” Journal of Pharmacological Sciences 127, no. 3 (2015): 275–283.

[156] W. Zheng, H. Song, Z. Luo, et al., “Acetylcholine Ameliorates Colitis by Promoting IL-10 Secretion of Monocytic Myeloid-Derived Suppressor Cells Through the nAChR/ERK Pathway,” Proceedings of the National Academy of Sciences of the United States of America 118, no. 11 (2021).

[157] S. D. AlSharari, W. Toma, H. M. Mahmood, et al., “The α9α10 Nicotinic Acetylcholine Receptors Antagonist α-Conotoxin RgIA Reverses Colitis Signs in Murine Dextran Sodium Sulfate Model,” European Journal of Pharmacology 883 (2020): 173320.

[158] G. Zhang, Y. Lian, Q. Li, et al., “Vagal Pathway Activation Links Chronic Stress to Decline in Intestinal Stem Cell Function,” Cell Stem Cell 32, no. 5 (2025): 778–794.e10.

[159] A. M. G. de Diego, L. Gandía, and A. G. García, “A Physiological View of the Central and Peripheral Mechanisms That Regulate the Release of Catecholamines at the Adrenal Medulla,” Acta Physiologica (Oxford, England) 192, no. 2 (2008): 287–301.

[160] M. Eriksson, B. Lindh, K. Uvnäs-Moberg, et al., “Distribution and Origin of Peptide-Containing Nerve Fibres in the Rat and Human Mammary Gland,” Neuroscience 70, no. 1 (1996): 227–245.

[161] C. Scheiermann, Y. Kunisaki, and P. S. Frenette, “Circadian Control of the Immune System,” Nature Reviews Immunology 13, no. 3 (2013): 190–198.

[162] E. J. Wood, “Marks' Basic Medical Biochemistry: A Clinical Approach (Second Edition),” Biochemistry and Molecular Biology Education: A Bimonthly Publication of the International Union of Biochemistry and Molecular Biology 34, no. 5 (2006): 395.

[163] J. H. Burn, D. E. Hutcheon, and R. H. O. Parker, “Adrenaline and Noradrenaline in the Suprarenal Medulla After Insulin,” British Journal of Pharmacology and Chemotherapy 5, no. 3 (1950): 417–423.

[164] J. Tang, Z. Li, L. Lu, et al., “β-Adrenergic System, a Backstage Manipulator Regulating Tumour Progression and Drug Target in Cancer Therapy,” Seminars in Cancer Biology 23, no. 6 pt. B (2013): 533–542.

[165] S. W. Cole, A. S. Nagaraja, S. K. Lutgendorf, et al., “Sympathetic Nervous System Regulation of the Tumour Microenvironment,” Nature Reviews Cancer 15, no. 9 (2015): 563–572.

[166] F. Marino and M. Cosentino, “Adrenergic Modulation of Immune Cells: An Update,” Amino Acids 45, no. 1 (2013): 55–71.

[167] D. M. Nance and V. M. Sanders, “Autonomic Innervation and Regulation of the Immune System (1987-2007),” Brain, Behavior, and Immunity 21, no. 6 (2007): 736–745.

[168] D. Kerage, E. K. Sloan, S. R. Mattarollo, et al., “Interaction of Neurotransmitters and Neurochemicals With Lymphocytes,” Journal of Neuroimmunology 332 (2019): 99–111.

[169] A. E. Carie and S. M. Sebti, “A Chemical Biology Approach Identifies a Beta-2 Adrenergic Receptor Agonist That Causes Human Tumor Regression by Blocking the Raf-1/Mek-1/Erk1/2 Pathway,” Oncogene 26, no. 26 (2007): 3777–3788.

[170] X. Zhang, Y. Zhang, Z. He, et al., “Chronic Stress Promotes Gastric Cancer Progression and Metastasis: An Essential Role for ADRB2,” Cell Death & Disease 10, no. 11 (2019): 788.

[171] H. P. Wong, J. W. Ho, M. W. Koo, et al., “Effects of Adrenaline in Human Colon Adenocarcinoma HT-29 Cells,” Life Sciences 88, no. 25–26 (2011): 1108–1112.

[172] X. Liu, W. K. K. Wu, L. Yu, et al., “Epinephrine Stimulates Esophageal Squamous-Cell Carcinoma Cell Proliferation via Beta-Adrenoceptor-Dependent Transactivation of Extracellular Signal-Regulated Kinase/Cyclooxygenase-2 Pathway,” Journal of Cellular Biochemistry 105, no. 1 (2008): 53–60.

[173] Y. Guan, W. Yao, H. Yu, et al., “Chronic Stress Promotes Colorectal Cancer Progression by Enhancing Glycolysis Through β2-AR/CREB1 Signal Pathway,” International Journal of Biological Sciences 19, no. 7 (2023): 2006–2019.

[174] H. Kobayashi, T. Iida, Y. Ochiai, et al., “Neuro-Mesenchymal Interaction Mediated by a β2-Adrenergic Nerve Growth Factor Feedforward Loop Promotes Colorectal Cancer Progression,” Cancer Discovery 15, no. 1 (2025): 202–226.

[175] P. H. Thaker, L. Y. Han, A. A. Kamat, et al., “Chronic Stress Promotes Tumor Growth and Angiogenesis in a Mouse Model of Ovarian Carcinoma,” Nature Medicine 12, no. 8 (2006): 939–944.

[176] Y. Zhou, P. Chu, Y. Wang, et al., “Epinephrine Promotes Breast Cancer Metastasis Through a Ubiquitin-Specific Peptidase 22-Mediated Lipolysis Circuit,” Science Advances 10, no. 33 (2024): eado1533.

[177] D. Palm, K. Lang, B. Niggemann, et al., “The Norepinephrine-Driven Metastasis Development of PC-3 Human Prostate Cancer Cells in BALB/c Nude Mice Is Inhibited by Beta-Blockers,” International Journal of Cancer 118, no. 11 (2006): 2744–2749.

[178] H. Park, S. Lee, and S. Park, “Norepinephrine Stimulates M2 Macrophage Polarization via β2-Adrenergic Receptor-Mediated IL-6 Production in Breast Cancer Cells,” Biochemical and Biophysical Research Communications 741 (2024): 151087.

[179] C. Kim-Fuchs, C. P. Le, M. A. Pimentel, et al., “Chronic Stress Accelerates Pancreatic Cancer Growth and Invasion: A Critical Role for Beta-Adrenergic Signaling in the Pancreatic Microenvironment,” Brain, Behavior, and Immunity 40 (2014): 40–47.

[180] R. Arreola, E. Becerril-Villanueva, C. Cruz-Fuentes, et al., “Immunomodulatory Effects Mediated by Serotonin,” Journal of Immunology Research 2015 (2015): 354957.

[181] J. Liu, L. Qu, C. Wan, et al., “A Novel β2-AR/YB-1/β-Catenin Axis Mediates Chronic Stress-Associated Metastasis in Hepatocellular Carcinoma,” Oncogenesis 9, no. 9 (2020): 84.

[182] M. Coelho, C. Soares-Silva, D. Brandão, et al., “β-Adrenergic Modulation of Cancer Cell Proliferation: Available Evidence and Clinical Perspectives,” Journal of Cancer Research and Clinical Oncology 143, no. 2 (2017): 275–291.

[183] K. Masur, B. Niggemann, K. S. Zanker, et al., “Norepinephrine-Induced Migration of SW 480 Colon Carcinoma Cells Is Inhibited by Beta-Blockers,” Cancer Research 61, no. 7 (2001): 2866–2869.

[184] K. Guo, Q. Ma, L. Wang, et al., “Norepinephrine-Induced Invasion by Pancreatic Cancer Cells Is Inhibited by Propranolol,” Oncology Reports 22, no. 4 (2009): 825–830.

[185] Z. Liu, C. Jian, W. Yuan, et al., “Epinephrine Promotes Tumor Progression and M2 Polarization of Tumor-Associated Macrophages by Regulating the TRIM2- NF-κB Pathway in Colorectal Cancer Cells,” Genes & Diseases 11, no. 4 (2023): 101092.

[186] M. D. Nissen, E. K. Sloan, and S. R. Mattarollo, “β-Adrenergic Signaling Impairs Antitumor CD8+ T-cell Responses to B-Cell Lymphoma Immunotherapy,” Cancer Immunology Research 6, no. 1 (2018): 98–109.

[187] L. Jean Wrobel, L. Bod, R. Lengagne, et al., “Propranolol Induces a Favourable Shift of Anti-Tumor Immunity in a Murine Spontaneous Model of Melanoma,” Oncotarget 7, no. 47 (2016): 77825–77837.

[188] H. Mohammadpour, C. R. MacDonald, G. Qiao, et al., “β2 Adrenergic Receptor-Mediated Signaling Regulates the Immunosuppressive Potential of Myeloid-Derived Suppressor Cells,” Journal of Clinical Investigation 129, no. 12 (2019): 5537–5552.

[189] C. Zhao, Y. Hayakawa, Y. Kodama, et al., “Denervation Suppresses Gastric Tumorigenesis,” Science Translational Medicine 6, no. 250 (2014): 250ra115.

[190] Q. Geng, L. Li, Z. Shen, et al., “Norepinephrine Inhibits CD8(+) T-Cell Infiltration and Function, Inducing Anti-PD-1 mAb Resistance in Lung Adenocarcinoma,” British Journal of Cancer 128, no. 7 (2023): 1223–1235.

[191] T. Kim, C. Ly, A. Christodoulides, et al., “Stress Hormone Signaling Through β-Adrenergic Receptors Regulates Macrophage Mechanotype and Function,” FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 33, no. 3 (2019): 3997–4006.

[192] E. K. Sloan, S. J. Priceman, B. F. Cox, et al., “The Sympathetic Nervous System Induces a Metastatic Switch in Primary Breast Cancer,” Cancer Research 70, no. 18 (2010): 7042–7052.

[193] E. Van Overmeire, B. Stijlemans, F. Heymann, et al., “M-CSF and GM-CSF Receptor Signaling Differentially Regulate Monocyte Maturation and Macrophage Polarization in the Tumor Microenvironment,” Cancer Research 76, no. 1 (2016): 35–42.

[194] M. Shi, D. Liu, Z. Yang, et al., “Central and Peripheral Nervous Systems: Master Controllers in Cancer Metastasis,” Cancer and Metastasis Reviews 32, no. 3–4 (2013): 603–621.

[195] A. Gosain, K. Muthu, R. L. Gamelli, et al., “Norepinephrine Suppresses Wound Macrophage Phagocytic Efficiency Through Alpha- and Beta-Adrenoreceptor Dependent Pathways,” Surgery 142, no. 2 (2007): 170–179.

[196] G. Eisenhofer, I. J. Kopin, and D. S. Goldstein, “Catecholamine Metabolism: A Contemporary View With Implications for Physiology and Medicine,” Pharmacological Reviews 56, no. 3 (2004): 331–349.

[197] C. Colosimo and A. Craus, “Noradrenergic Drugs for Levodopa-Induced Dyskinesia,” Clinical Neuropharmacology 26, no. 6 (2003): 299–305.

[198] F. Fornai, A. B. di Poggio, A. Pellegrini, et al., “Noradrenaline in Parkinson's Disease: From Disease Progression to Current Therapeutics,” Current Medicinal Chemistry 14, no. 22 (2007): 2330–2334.

[199] D. Weinshenker, “Long Road to Ruin: Noradrenergic Dysfunction in Neurodegenerative Disease,” Trends in Neurosciences 41, no. 4 (2018): 211–223.

[200] Y. Xu, J. Yan, P. Zhou, et al., “Neurotransmitter Receptors and Cognitive Dysfunction in Alzheimer's Disease and Parkinson's Disease,” Progress in Neurobiology 97, no. 1 (2012): 1–13.

[201] C. Colosimo, G. Fabbrini, and A. Berardelli, “Drug Insight: New Drugs in Development for Parkinson's Disease,” Nature Clinical Practice Neurology 2, no. 11 (2006): 600–610.

[202] P. Barone, “Neurotransmission in Parkinson's Disease: Beyond Dopamine,” European Journal of Neurology 17, no. 3 (2010): 364–376.

[203] H. I. L. Jacobs, J. A. Becker, K. Kwong, et al., “In Vivo and Neuropathology Data Support Locus Coeruleus Integrity as Indicator of Alzheimer's Disease Pathology and Cognitive Decline,” Science Translational Medicine 13, no. 612 (2021): eabj2511.

[204] K. J. Reinikainen, L. Paljärvi, M. Huuskonen, et al., “A Post-Mortem Study of Noradrenergic, Serotonergic and GABAergic Neurons in Alzheimer's Disease,” Journal of the Neurological Sciences 84, no. 1 (1988): 101–116.

[205] D. Storga, K. Vrecko, J. G. Birkmayer, et al., “Monoaminergic Neurotransmitters, Their Precursors and Metabolites in Brains of Alzheimer Patients,” Neuroscience Letters 203, no. 1 (1996): 29–32.

[206] X. Pan, A. C. Kaminga, P. Jia, et al., “Catecholamines in Alzheimer's Disease: A Systematic Review and Meta-Analysis,” Frontiers in Aging Neuroscience 12 (2020): 184.

[207] L. L. Iversen, M. N. Rossor, G. P. Reynolds, et al., “Loss of Pigmented Dopamine-Beta-Hydroxylase Positive Cells From Locus Coeruleus in Senile Dementia of Alzheimer's Type,” Neuroscience Letters 39, no. 1 (1983): 95–100.

[208] K. Henjum, L. O. Watne, K. Godang, et al., “Cerebrospinal Fluid Catecholamines in Alzheimer's Disease Patients With and Without Biological Disease,” Translational Psychiatry 12, no. 1 (2022): 151.

[209] A. F. Iannitelli, M. A. Kelberman, D. J. Lustberg, et al., “The Neurotoxin DSP-4 Dysregulates the Locus Coeruleus-Norepinephrine System and Recapitulates Molecular and Behavioral Aspects of Prodromal Neurodegenerative Disease,” ENeuro 10, no. 1 (2023): ENEURO.0483–22.2022.

[210] Y. Liu, M. Yoo, A. Savonenko, et al., “Amyloid Pathology Is Associated With Progressive Monoaminergic Neurodegeneration in a Transgenic Mouse Model of Alzheimer's Disease,” Journal of Neuroscience: The Official Journal of the Society for Neuroscience 28, no. 51 (2008): 13805–13814.

[211] M. T. Heneka, E. Galea, V. Gavriluyk, et al., “Noradrenergic Depletion Potentiates Beta-Amyloid-Induced Cortical Inflammation: Implications for Alzheimer's Disease,” Journal of Neuroscience: The Official Journal of the Society for Neuroscience 22, no. 7 (2002): 2434–2442.

[212] M. T. Heneka, F. Nadrigny, T. Regen, et al., “Locus Ceruleus Controls Alzheimer's Disease Pathology by Modulating Microglial Functions Through Norepinephrine,” Proceedings of the National Academy of Sciences of the United States of America 107, no. 13 (2010): 6058–6063.

[213] J. L. M. Madrigal, S. Kalinin, J. C. Richardson, et al., “Neuroprotective Actions of Noradrenaline: Effects on Glutathione Synthesis and Activation of Peroxisome Proliferator Activated Receptor Delta,” Journal of Neurochemistry 103, no. 5 (2007): 2092–2101.

[214] J. H. Yang, E. O. Lee, S. E. Kim, et al., “Norepinephrine Differentially Modulates the Innate Inflammatory Response Provoked by Amyloid-β Peptide via Action at β-Adrenoceptors and Activation of cAMP/PKA Pathway in Human THP-1 Macrophages,” Experimental Neurology 236, no. 2 (2012): 199–206.

[215] Y. Kong, L. Ruan, L. Qian, et al., “Norepinephrine Promotes Microglia to Uptake and Degrade Amyloid Beta Peptide Through Upregulation of Mouse Formyl Peptide Receptor 2 and Induction of Insulin-Degrading Enzyme,” Journal of Neuroscience: The Official Journal of the Society For Neuroscience 30, no. 35 (2010): 11848–11857.

[216] E. J. Siddiqui, C. S. Thompson, D. P. Mikhailidis, et al., “The Role of Serotonin in Tumour Growth (Review),” Oncology Reports 14, no. 6 (2005): 1593–1597.

[217] T. Shinka, D. Onodera, T. Tanaka, et al., “Serotonin Synthesis and Metabolism-Related Molecules in a Human Prostate Cancer Cell Line,” Oncology Letters 2, no. 2 (2011): 211–215.

[218] C. Jonnakuty and C. Gragnoli, “What Do We Know About Serotonin?” Journal of Cellular Physiology 217, no. 2 (2008): 301–306.

[219] E. Mammadova-Bach, M. Mauler, A. Braun, et al., “Autocrine and Paracrine Regulatory Functions of Platelet Serotonin,” Platelets 29, no. 6 (2018): 541–548.

[220] D. Hoyer, D. E. Clarke, J. R. Fozard, et al., “International Union of Pharmacology Classification of Receptors for 5-Hydroxytryptamine (Serotonin),” Pharmacological Reviews 46, no. 2 (1994): 157–203.

[221] D. Ye, H. Xu, Q. Tang, et al., “The Role of 5-HT Metabolism in Cancer,” Biochimica et Biophysica Acta: Reviews on Cancer 1876, no. 2 (2021): 188618.

[222] P. Balakrishna, S. George, H. Hatoum, et al., “Serotonin Pathway in Cancer,” International Journal of Molecular Sciences 22, no. 3 (2021): 1268.

[223] D. Sarrouilhe, J. Clarhaut, N. Defamie, et al., “Serotonin and Cancer: What Is the Link?” Current Molecular Medicine 15, no. 1 (2015): 62–77.

[224] N. Dizeyi, A. Bjartell, E. Nilsson, et al., “Expression of Serotonin Receptors and Role of Serotonin in Human Prostate Cancer Tissue and Cell Lines,” Prostate 59, no. 3 (2004): 328–336.

[225] E. J. Siddiqui, M. Shabbir, D. P. Mikhailidis, et al., “The Role of Serotonin (5-Hydroxytryptamine1A and 1B) Receptors in Prostate Cancer Cell Proliferation,” Journal of Urology 176, no. 4 pt. 1 (2006): 1648–1653.

[226] N. Dizeyi, A. Bjartell, P. Hedlund, et al., “Expression of Serotonin Receptors 2B and 4 in Human Prostate Cancer Tissue and Effects of Their Antagonists on Prostate Cancer Cell Lines,” European Urology 47, no. 6 (2005): 895–900.

[227] F. Del Bello, A. Bonifazi, G. Giorgioni, et al., “Chemical Manipulations on the 1,4-Dioxane Ring of 5-HT1A Receptor Agonists Lead to Antagonists Endowed With Antitumor Activity in Prostate Cancer Cells,” European Journal of Medicinal Chemistry 168 (2019): 461–473.

[228] D. Sarrouilhe, J. Clarhaut, N. Defamie, et al., “Serotonin and Cancer: What Is the Link?” Current Molecular Medicine 15, no. 1 (2015): 62–77.

[229] T. Shinka, D. Onodera, T. Tanaka, et al., “Serotonin Synthesis and Metabolism-Related Molecules in a Human Prostate Cancer Cell Line,” Oncology Letters 2, no. 2 (2011): 211–215.

[230] V. P. Pai, A. M. Marshall, L. L. Hernandez, et al., “Altered Serotonin Physiology in Human Breast Cancers Favors Paradoxical Growth and Cell Survival,” Breast Cancer Research 11, no. 6 (2009): R81.

[231] M. G. Cattaneo, E. Palazzi, G. Bondiolotti, et al., “5-HT1D Receptor Type Is Involved in Stimulation of Cell Proliferation by Serotonin in Human Small Cell Lung Carcinoma,” European Journal of Pharmacology 268, no. 3 (1994): 425–430.

[232] M. G. Cattaneo, E. Palazzi, G. Bondiolotti, et al., “5-HT1D Receptor Type Is Involved in Stimulation of Cell Proliferation by Serotonin in Human Small Cell Lung Carcinoma,” European Journal of Pharmacology 268, no. 3 (1994): 425–430.

[233] M. G. Cattaneo, R. Fesce, and L. M. Vicentini, “Mitogenic Effect of Serotonin in Human Small Cell Lung Carcinoma Cells via Both 5-HT1A and 5-HT1D Receptors,” European Journal of Pharmacology 291, no. 2 (1995): 209–211.

[234] L. M. Vicentini, M. G. Cattaneo, and R. Fesce, “Evidence for Receptor Subtype Cross-Talk in the Mitogenic Action of Serotonin on Human Small-Cell Lung Carcinoma Cells,” European Journal of Pharmacology 318, no. 2–3 (1996): 497–504.

[235] T. Li, B. Fu, X. Zhang, et al., “Overproduction of Gastrointestinal 5-HT Promotes Colitis-Associated Colorectal Cancer Progression via Enhancing NLRP3 Inflammasome Activation,” Cancer Immunology Research 9, no. 9 (2021): 1008–1023.

[236] R. Ataee, S. Ajdary, M. Zarrindast, et al., “Anti-Mitogenic and Apoptotic Effects of 5-HT1B Receptor Antagonist on HT29 Colorectal Cancer Cell Line,” Journal of Cancer Research and Clinical Oncology 136, no. 10 (2010): 1461–1469.

[237] R. Ataee, S. Ajdary, M. Rezayat, et al., “Study of 5HT3 and HT4 Receptor Expression in HT29 Cell Line and Human Colon Adenocarcinoma Tissues,” Archives of Iranian Medicine 13, no. 2 (2010): 120–125.

[238] S. Karmakar and G. Lal, “Role of Serotonin Receptor Signaling in Cancer Cells and Anti-Tumor Immunity,” Theranostics 11, no. 11 (2021): 5296–5312.

[239] N. Dizeyi, P. Hedlund, A. Bjartell, et al., “Serotonin Activates MAP Kinase and PI3K/Akt Signaling Pathways in Prostate Cancer Cell Lines,” Urologic Oncology 29, no. 4 (2011): 436–445.

[240] N. Gurbuz, A. A. Ashour, S. N. Alpay, et al., “Down-Regulation of 5-HT1B and 5-HT1D Receptors Inhibits Proliferation, Clonogenicity and Invasion of Human Pancreatic Cancer Cells,” PLoS ONE 9, no. 8 (2014): e105245.

[241] R. Tu, S. Wu, Z. Huang, et al., “Neurotransmitter Receptor HTR2B Regulates Lipid Metabolism to Inhibit Ferroptosis in Gastric Cancer,” Cancer Research 83, no. 23 (2023): 3868–3885.

[242] Y. Tu, S. Yao, Q. Chen, et al., “5-Hydroxytryptamine Activates a 5-HT/c-Myc/SLC6A4 Signaling Loop in Non-Small Cell Lung Cancer,” Biochimica et Biophysica Acta – General Subjects 1866, no. 4 (2022): 130093.

[243] J. Gautam, Y. K. Bae, and J. A. Kim, “Up-Regulation of Cathepsin S Expression by HSP90 and 5-HT(7) Receptor-Dependent Serotonin Signaling Correlates With Triple Negativity of Human Breast Cancer,” Breast Cancer Research and Treatment 161, no. 1 (2017): 29–40.

[244] J. Gautam, S. Banskota, S. C. Regmi, et al., “Tryptophan Hydroxylase 1 and 5-HT(7) Receptor Preferentially Expressed in Triple-Negative Breast Cancer Promote Cancer Progression Through Autocrine Serotonin Signaling,” Molecular Cancer 15, no. 1 (2016): 75.

[245] S. Banskota, J. Gautam, S. C. Regmi, et al., “BJ-1108, a 6-Amino-2,4,5-Trimethylpyridin-3-ol Analog, Inhibits Serotonin-Induced Angiogenesis and Tumor Growth Through PI3K/NOX Pathway,” PLoS ONE 11, no. 1 (2016): e0148133.

[246] V. Kannen, S. B. Garcia, W. A. Silva, et al., “Oncostatic Effects of Fluoxetine in Experimental Colon Cancer Models,” Cell Signalling 27, no. 9 (2015): 1781–1788.

[247] F. Abedini, O. Amjadi, A. Hedayatizadeh-Omran, et al., “Serotonin Receptors and Acetylcholinesterase Gene Expression Alternations: The Potential Value on Tumor Microenvironment of Gastric Cancer,” Oncology 101, no. 7 (2023): 415–424.

[248] T. Li, B. Fu, X. Zhang, et al., “Overproduction of Gastrointestinal 5-HT Promotes Colitis-Associated Colorectal Cancer Progression via Enhancing NLRP3 Inflammasome Activation,” Cancer Immunology Research 9, no. 9 (2021): 1008–1023.

[249] V. Kannen, M. Bader, J. Y. Sakita, et al., “The Dual Role of Serotonin in Colorectal Cancer,” Trends in Endocrinology and Metabolism 31, no. 8 (2020): 611–625.

[250] I. Cloëz-Tayarani, A. F. Petit-Bertron, H. D. Venters, et al., “Differential Effect of Serotonin on Cytokine Production in Lipopolysaccharide-Stimulated Human Peripheral Blood Mononuclear Cells: Involvement of 5-Hydroxytryptamine2A Receptors,” International Immunology 15, no. 2 (2003): 233–240.

[251] M. de las Casas-Engel, A. Domínguez-Soto, E. Sierra-Filardi, et al., “Serotonin Skews Human Macrophage Polarization Through HTR2B and HTR7,” Journal of Immunology 190, no. 5 (2013): 2301–2310.

[252] N. A. Khan and J. P. Poisson, “5-HT3 Receptor-Channels Coupled With Na⁺ Influx in Human T Cells: Role in T Cell Activation,” Journal of Neuroimmunology 99, no. 1 (1999): 53–60.

[253] P. J. O'Connell, X. Wang, M. Leon-Ponte, et al., “A Novel Form of Immune Signaling Revealed by Transmission of the Inflammatory Mediator Serotonin Between Dendritic Cells and T Cells,” Blood 107, no. 3 (2006): 1010–1017.

[254] M. León-Ponte, G. P. Ahern, and P. J. O'Connell, “Serotonin Provides an Accessory Signal to Enhance T-Cell Activation by Signaling Through the 5-HT7 Receptor,” Blood 109, no. 8 (2007): 3139–3146.

[255] B. Li, J. Elsten-Brown, M. Li, et al., “Serotonin Transporter Inhibits Antitumor Immunity Through Regulating the Intratumoral Serotonin Axis,” Cell 188, no. 14 (2025): 3823–3842.

[256] X. Wang, S. Fu, X. Yuan, et al., “A GAPDH Serotonylation System Couples CD8+ T Cell Glycolytic Metabolism to Antitumor Immunity,” Molecular Cell 84, no. 4 (2024): 760–775.

[257] B. L. Jacobs and E. C. Azmitia, “Structure and Function of the Brain Serotonin System,” Physiological Reviews 72, no. 1 (1992): 165–229.

[258] R. D. Rubin, P. D. Watson, M. C. Duff, et al., “The Role of the Hippocampus in Flexible Cognition and Social Behavior,” Frontiers in Human Neuroscience 8 (2014): 742.

[259] Y. Glikmann-Johnston, M. M. Saling, D. C. Reutens, et al., “Hippocampal 5-HT1A Receptor and Spatial Learning and Memory,” Frontiers in Pharmacology 6 (2015): 289.

[260] S. Chakraborty, J. C. Lennon, S. A. Malkaram, et al., “Serotonergic System, Cognition, and BPSD in Alzheimer's Disease,” Neuroscience Letters 704 (2019): 36–44.

[261] Y. Ohno, S. Shimizu, K. Tokudome, et al., “New Insight Into the Therapeutic Role of the Serotonergic System in Parkinson's Disease,” Progress in Neurobiology 134 (2015): 104–121.

[262] J. Reijnders, U. Ehrt, W. E. J. Weber, et al., “A Systematic Review of Prevalence Studies of Depression in Parkinson's Disease,” Movement Disorders: Official Journal of the Movement Disorder Society 23, no. 2 (2008): 183–189.

[263] K. A. Jellinger, “Neuropathobiology of Non-Motor Symptoms in Parkinson Disease,” Journal of Neural Transmission (Vienna, Austria: 1996) 122, no. 10 (2015): 1429–1440.

[264] S. J. Kish, J. Tong, O. Hornykiewicz, et al., “Preferential Loss of Serotonin Markers in Caudate Versus Putamen in Parkinson's Disease,” Brain: A Journal of Neurology 131, no. pt. 1 (2008): 120–131.

[265] D. Rylander, M. Parent, S. S. O'Sullivan, et al., “Maladaptive Plasticity of Serotonin Axon Terminals in Levodopa-Induced Dyskinesia,” Annals of Neurology 68, no. 5 (2010): 619–628.

[266] E. R. de Natale, H. Wilson, and M. Politis, “Serotonergic Imaging in Parkinson's Disease,” Progress in Brain Research 261 (2021): 303–338.

[267] G. Pagano, F. Niccolini, P. Fusar-Poli, et al., “Serotonin Transporter in Parkinson's Disease: A Meta-Analysis of Positron Emission Tomography Studies,” Annals of Neurology 81, no. 2 (2017): 171–180.

[268] J. Pasquini, R. Ceravolo, Z. Qamhawi, et al., “Progression of Tremor in Early Stages of Parkinson's Disease: A Clinical and Neuroimaging Study,” Brain: A Journal of Neurology 141, no. 3 (2018): 811–821.

[269] R. Djaldetti, S. Yust-Katz, V. Kolianov, et al., “The Effect of Duloxetine on Primary Pain Symptoms in Parkinson Disease,” Clinical Neuropharmacology 30, no. 4 (2007): 201–205.

[270] C. Miguelez, T. Morera-Herreras, M. Torrecilla, et al., “Interaction Between the 5-HT System and the Basal Ganglia: Functional Implication and Therapeutic Perspective in Parkinson's Disease,” Frontiers in Neural Circuits 8 (2014): 21.

[271] A. Pinna, P. Parekh, and M. Morelli, “Serotonin 5-HT1A Receptors and Their Interactions With Adenosine A2A Receptors in Parkinson's Disease and Dyskinesia,” Neuropharmacology 226 (2023): 109411.

[272] K. D. Alex and E. A. Pehek, “Pharmacologic Mechanisms of Serotonergic Regulation of Dopamine Neurotransmission,” Pharmacology & Therapeutics 113, no. 2 (2007): 296–320.

[273] S. Cellek, A. K. John, R. Thangiah, et al., “5-HT4 Receptor Agonists Enhance Both Cholinergic and Nitrergic Activities in Human Isolated Colon Circular Muscle,” Neurogastroenterology and Motility 18, no. 9 (2006): 853–861.

[274] R. A. McDevitt and J. F. Neumaier, “Regulation of Dorsal Raphe Nucleus Function by Serotonin Autoreceptors: A Behavioral Perspective,” Journal of Chemical Neuroanatomy 41, no. 4 (2011): 234–246.

[275] M. A. Cenci, K. Skovgård, and P. Odin, “Non-Dopaminergic Approaches to the Treatment of Motor Complications in Parkinson's Disease,” Neuropharmacology 210 (2022): 109027.

[276] M. Garcia-Alloza, G. FJ, M. Diez-Ariza, et al., “Cholinergic-Serotonergic Imbalance Contributes to Cognitive and Behavioral Symptoms in Alzheimer's Disease,” Neuropsychologia 43, no. 3 (2005): 442–449.

[277] C. G. Gottfries, “Disturbance of the 5-Hydroxytryptamine Metabolism in Brains From Patients With Alzheimer's Dementia,” Journal of Neural Transmission 30, no. suppl. (1990): 33–43.

[278] V. Kepe, J. R. Barrio, S. Huang, et al., “Serotonin 1A Receptors in the Living Brain of Alzheimer's Disease Patients,” Proceedings of the National Academy of Sciences of the United States of America 103, no. 3 (2006): 702–707.

[279] M. Garcia-Alloza, W. D. Hirst, C. Chen, et al., “Differential Involvement of 5-HT(1B/1D) and 5-HT6 Receptors in Cognitive and Non-Cognitive Symptoms in Alzheimer's Disease,” Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 29, no. 2 (2004): 410–416.

[280] P. Holm, A. Ettrup, A. B. Klein, et al., “Plaque Deposition Dependent Decrease in 5-HT2A Serotonin Receptor in AbetaPPswe/PS1dE9 Amyloid Overexpressing Mice,” Journal of Alzheimer's Disease: JAD 20, no. 4 (2010): 1201–1213.

[281] J. Versijpt, K. J. Van Laere, F. Dumont, et al., “Imaging of the 5-HT2A System: Age-, Gender-, and Alzheimer's Disease-Related Findings,” Neurobiology of Aging 24, no. 4 (2003): 553–561.

[282] M. K. Lai, S. W. Tsang, P. T. Francis, et al., “[3H]GR113808 Binding to Serotonin 5-HT(4) Receptors in the Postmortem Neocortex of Alzheimer Disease: A Clinicopathological Study,” Journal of Neural Transmission (Vienna, Austria: 1996) 110, no. 7 (2003): 779–788.

[283] M. Cochet, R. Donneger, E. Cassier, et al., “5-HT4 Receptors Constitutively Promote the Non-Amyloidogenic Pathway of APP Cleavage and Interact With ADAM10,” ACS Chemical Neuroscience 4, no. 1 (2013): 130–140.

[284] A. A. Arjona, A. M. Pooler, R. K. Lee, et al., “Effect of a 5-HT(2C) Serotonin Agonist, Dexnorfenfluramine, on Amyloid Precursor Protein Metabolism in Guinea Pigs,” Brain Research 951, no. 1 (2002): 135–140.

[285] G. S. Perez-García and A. Meneses, “Effects of the Potential 5-HT7 Receptor Agonist AS 19 in an Autoshaping Learning Task,” Behavioural Brain Research 163, no. 1 (2005): 136–140.

[286] N. Hashemi-Firouzi, A. Komaki, S. Soleimani Asl, et al., “The Effects of the 5-HT7 Receptor on Hippocampal Long-Term Potentiation and Apoptosis in a Rat Model of Alzheimer's Disease,” Brain Research Bulletin 135 (2017): 85–91.

[287] R. Rahimian, G. Fakhfouri, S. Ejtemaei Mehr, et al., “Tropisetron Attenuates Amyloid-Beta-Induced Inflammatory and Apoptotic Responses in Rats,” European Journal of Clinical Investigation 43, no. 10 (2013): 1039–1051.

[288] B. Ju Yeon and S. Yeon Hee, “Blockade of 5-HT(3) Receptor with MDL 72222 and Y 25130 Reduces Beta-Amyloid Protein (25–35)-Induced Neurotoxicity in Cultured Rat Cortical Neurons,” European Journal of Pharmacology 520, no. 1–3 (2005): 12–21.

[289] D. E. Lorke, G. Lu, E. Cho, et al., “Serotonin 5-HT2A and 5-HT6 Receptors in the Prefrontal Cortex of Alzheimer and Normal Aging Patients,” BMC Neuroscience 7 (2006): 36.

[290] H. Yun, K. Park, E. Kim, et al., “Serotonin 6 Receptor Controls Alzheimer's Disease and Depression,” Oncotarget 6, no. 29 (2015): 26716–26728.

[291] C. L. Busceti, P. Di Pietro, B. Riozzi, et al., “5-HT(2C) Serotonin Receptor Blockade Prevents Tau Protein Hyperphosphorylation and Corrects the Defect in Hippocampal Synaptic Plasticity Caused by a Combination of Environmental Stressors in Mice,” Pharmacological Research 99 (2015): 258–268.

[292] A. P. Reddy, P. Rawat, N. Rohr, et al., “Role of Serotonylation and SERT Posttranslational Modifications in Alzheimer's Disease Pathogenesis,” Aging and Disease 16, no. 2 (2024): 841–858.

[293] A. Rapalli, S. Bertoni, V. Arcaro, et al., “Dual Role of Endogenous Serotonin in 2,4,6-Trinitrobenzene Sulfonic Acid-Induced Colitis,” Frontiers in Pharmacology 7 (2016): 68.

[294] J. Xiao, L. Shao, J. Shen, et al., “Effects of Ketanserin on Experimental Colitis in Mice and Macrophage Function,” International Journal of Molecular Medicine 37, no. 3 (2016): 659–668.

[295] C. Rang, J. E. Galen, J. B. Kaper, et al., “Fitness Cost of the Green Fluorescent Protein in Gastrointestinal Bacteria,” Canadian Journal of Microbiology 49, no. 9 (2003): 531–537.

[296] M. Liu, Y. Kuan, J. Wang, et al., “5-HT4 Receptor-Mediated Neuroprotection and Neurogenesis in the Enteric Nervous System of Adult Mice,” Journal of Neuroscience: The Official Journal of the Society for Neuroscience 29, no. 31 (2009): 9683–9699.

[297] S. N. Spohn, F. Bianco, R. B. Scott, et al., “Protective Actions of Epithelial 5-Hydroxytryptamine 4 Receptors in Normal and Inflamed Colon,” Gastroenterology 151, no. 5 (2016): 933–944.e3.

[298] J. J. Kim, B. W. Bridle, J. Ghia, et al., “Targeted Inhibition of Serotonin Type 7 (5-HT7) Receptor Function Modulates Immune Responses and Reduces the Severity of Intestinal Inflammation,” Journal of Immunology (Baltimore, Md) 190, no. 9 (2013): 4795–4804.

[299] D. Guseva, K. Holst, B. Kaune, et al., “Serotonin 5-HT7 Receptor Is Critically Involved in Acute and Chronic Inflammation of the Gastrointestinal Tract,” Inflammatory Bowel Diseases 20, no. 9 (2014): 1516–1529.

[300] I. Cloëz-Tayarani and J. Changeux, “Nicotine and Serotonin in Immune Regulation and Inflammatory Processes: A Perspective,” Journal of Leukocyte Biology 81, no. 3 (2007): 599–606.

[301] H. Zhang, Y. Hasegawa, M. Suzuki, et al., “Mouse Enteric Neurons Control Intestinal Plasmacytoid Dendritic Cell Function via Serotonin-HTR7 Signaling,” Nature Communications 15, no. 1 (2024): 9237.

[302] K. Nakamura, T. Sato, A. Ohashi, et al., “Role of a Serotonin Precursor in Development of Gut Microvilli,” American Journal of Pathology 172, no. 2 (2008): 333–344.

[303] J. R. O'Hara, A. C. Skinn, W. K. MacNaughton, et al., “Consequences of Citrobacter rodentium Infection on Enteroendocrine Cells and the Enteric Nervous System in the Mouse Colon,” Cellular Microbiology 8, no. 4 (2006): 646–660.

[304] J. Wheatcroft, D. Wakelin, A. Smith, et al., “Enterochromaffin Cell Hyperplasia and Decreased Serotonin Transporter in a Mouse Model of Postinfectious Bowel Dysfunction,” Neurogastroenterology and Motility 17, no. 6 (2005): 863–870.

[305] Y. Bhattarai, B. A. Schmidt, D. R. Linden, et al., “Human-Derived Gut Microbiota Modulates Colonic Secretion in Mice by Regulating 5-HT3 Receptor Expression via Acetate Production,” American Journal of Physiology Gastrointestinal and Liver Physiology 313, no. 1 (2017): G80–G87.

[306] X. Ge, C. Ding, W. Zhao, et al., “Antibiotics-Induced Depletion of Mice Microbiota Induces Changes in Host Serotonin Biosynthesis and Intestinal Motility,” Journal of Translational Medicine 15, no. 1 (2017): 13.

[307] T. B. Legan, B. Lavoie, and G. M. Mawe, “Direct and Indirect Mechanisms by Which the Gut Microbiota Influence Host Serotonin Systems,” Neurogastroenterology and Motility 34, no. 10 (2022): e14346.

[308] B. A. Everett, P. Tran, and A. Prindle, “Toward Manipulating Serotonin Signaling via the Microbiota-Gut-Brain Axis,” Current Opinion In Biotechnology 78 (2022): 102826.

[309] S. Oshima, M. Fujimura, and M. Fukimiya, “Changes in Number of Serotonin-Containing Cells and Serotonin Levels in the Intestinal Mucosa of Rats With Colitis Induced by Dextran Sodium Sulfate,” Histochemistry and Cell Biology 112, no. 4 (1999): 257–263.

[310] D. R. Linden, J. Chen, M. D. Gershon, et al., “Serotonin Availability Is Increased in Mucosa of Guinea Pigs With TNBS-Induced Colitis,” American Journal of Physiology Gastrointestinal and Liver Physiology 285, no. 1 (2003): G207–G216.

[311] K. G. Margolis and C. Pothoulakis, “Serotonin Has a Critical Role in the Pathogenesis of Experimental Colitis,” Gastroenterology 137, no. 5 (2009): 1562–1566.

[312] K. G. Margolis, K. Stevanovic, Z. Li, et al., “Pharmacological Reduction of Mucosal but not Neuronal Serotonin Opposes Inflammation in Mouse Intestine,” Gut 63, no. 6 (2014): 928–937.

[313] K. Gross Margolis, J. Vittorio, M. Talavera, et al., “Enteric Serotonin and Oxytocin: Endogenous Regulation of Severity in a Murine Model of Necrotizing Enterocolitis,” American Journal of Physiology Gastrointestinal and Liver Physiology 313, no. 5 (2017): G386–G398.

[314] F. Magro, M. A. Vieira-Coelho, S. Fraga, et al., “Impaired Synthesis or Cellular Storage of Norepinephrine, Dopamine, and 5-Hydroxytryptamine in Human Inflammatory Bowel Disease,” Digestive Diseases and Sciences 47, no. 1 (2002): 216–224.

[315] L. Kennedy, K. Hodges, F. Meng, et al., “Histamine and Histamine Receptor Regulation of Gastrointestinal Cancers,” Translational Gastrointestinal Cancer 1, no. 3 (2012): 215–227.

[316] D. G. Ebo, C. H. Bridts, C. H. Mertens, et al., “Analyzing Histamine Release by Flow Cytometry (HistaFlow): A Novel Instrument to Study the Degranulation Patterns of Basophils,” Journal of Immunological Methods 375, no. 1–2 (2012): 30–38.

[317] Z. Li, J. Liu, F. Tang, et al., “Expression of Non-Mast Cell Histidine Decarboxylase in Tumor-Associated Microvessels in Human Esophageal Squamous Cell Carcinomas,” APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica 116, no. 12 (2008): 1034–1042.

[318] A. Tanimoto, Y. Matsuki, T. Tomita, et al., “Histidine Decarboxylase Expression in Pancreatic Endocrine Cells and Related Tumors,” Pathology International 54, no. 6 (2004): 408–412.

[319] K. Yatsunami, T. Fukui, and A. Ichikawa, “Molecular Biology of L-Histidine Decarboxylase,” Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan 114, no. 11 (1994): 803–822.

[320] H. A. Sterle, M. B. Nicoud, N. A. Massari, et al., “Immunomodulatory Role of Histamine H4 Receptor in Breast Cancer,” British Journal of Cancer 120, no. 1 (2019): 128–138.

[321] M. Sarasola, M. A. Táquez Delgado, M. B. Nicoud, et al., “Histamine in Cancer Immunology and Immunotherapy. Current Status and New Perspectives,” Pharmacology Research & Perspectives 9, no. 5 (2021): e00778.

[322] M. Wang, X. Wei, L. Shi, et al., “Integrative Genomic Analyses of the Histamine H1 Receptor and Its Role in Cancer Prediction,” International Journal of Molecular Medicine 33, no. 4 (2014): 1019–1026.

[323] A. Falus and K. Merétey, “Histamine: An Early Messenger in Inflammatory and Immune Reactions,” Immunology Today 13, no. 5 (1992): 154–156.

[324] L. Leino and E. M. Lilius, “Histamine Receptors on Leukocytes Are Expressed Differently In Vitro and Ex Vivo,” International Archives of Allergy and Applied Immunology 91, no. 1 (1990): 30–35.

[325] P. Panula, P. L. Chazot, M. Cowart, et al., “International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors,” Pharmacological Reviews 67, no. 3 (2015): 601–655.

[326] M. B. Nicoud, K. Formoso, and V. A. Medina, “Pathophysiological Role of Histamine H4 Receptor in Cancer: Therapeutic Implications,” Frontiers in Pharmacology 10 (2019): 556.

[327] G. He, J. Ding, X. Zhang, et al., “Activation of Histamine H4 Receptor Suppresses the Proliferation and Invasion of Esophageal Squamous Cell Carcinoma via Both Metabolism and Non-Metabolism Signaling Pathways,” Journal of Molecular Medicine (Berlin, Germany) 96, no. 9 (2018): 951–964.

[328] C. Zhang, Y. Xiong, J. Li, et al., “Deletion and Down-Regulation of HRH4 Gene in Gastric Carcinomas: A Potential Correlation With Tumor Progression,” PLoS ONE 7, no. 2 (2012): e31207.

[329] W. Cai, J. Hu, T. Li, et al., “Activation of Histamine H4 Receptors Decreases Epithelial-to-Mesenchymal Transition Progress by Inhibiting Transforming Growth Factor-β1 Signalling Pathway in Non-Small Cell Lung Cancer,” European Journal of Cancer (Oxford, England: 1990) 50, no. 6 (2014): 1195–1206.

[330] R. Seifert, A. Strasser, E. H. Schneider, et al., “Molecular and Cellular Analysis of Human Histamine Receptor Subtypes,” Trends in Pharmacological Sciences 34, no. 1 (2013): 33–58.

[331] A. Strasser, H. Wittmann, A. Buschauer, et al., “Species-Dependent Activities of G-Protein-Coupled Receptor Ligands: Lessons From Histamine Receptor Orthologs,” Trends in Pharmacological Sciences 34, no. 1 (2013): 13–32.

[332] N. A. Massari, M. B. Nicoud, and V. A. Medina, “Histamine Receptors and Cancer Pharmacology: An Update,” British Journal of Pharmacology 177, no. 3 (2020): 516–538.

[333] M. Liu, Y. Zhang, Q. Xu, et al., “Apigenin Inhibits the Histamine-Induced Proliferation of Ovarian Cancer Cells by Downregulating ERα/ERβ Expression,” Frontiers in Oncology 11 (2021): 682917.

[334] G. Losurdo, M. Principi, B. Girardi, et al., “Histamine and Histaminergic Receptors in Colorectal Cancer: From Basic Science to Evidence-Based Medicine,” Anti-Cancer Agents in Medicinal Chemistry 18, no. 1 (2018): 15–20.

[335] K. Boer, E. Helinger, A. Helinger, et al., “Decreased Expression of Histamine H1 and H4 Receptors Suggests Disturbance of Local Regulation in Human Colorectal Tumours by Histamine,” European Journal of Cell Biology 87, no. 4 (2008): 227–236.

[336] Z. Fang, W. Yao, Y. Xiong, et al., “Attenuated Expression of HRH4 in Colorectal Carcinomas: A Potential Influence on Tumor Growth and Progression,” BMC Cancer 11 (2011): 195.

[337] H. J. Lee, M. K. Park, E. J. Lee, et al., “Histamine Receptor 2-Mediated Growth-Differentiation Factor-15 Expression Is Involved in Histamine-Induced Melanogenesis,” International Journal of Biochemistry & Cell Biology 44, no. 12 (2012): 2124–2128.

[338] M. Höcker, Z. Zhang, T. J. Koh, et al., “The Regulation of Histidine Decarboxylase Gene Expression,” Yale Journal of Biology and Medicine 69, no. 1 (1996): 21–33.

[339] C. Jiang, F. Liu, M. Yu, et al., “Cimetidine Induces Apoptosis in Gastric Cancer Cells In Vitro and Inhibits Tumor Growth In Vivo,” Oncology Reports 23, no. 3 (2010): 693–700.

[340] E. S. Rivera, G. P. Cricco, N. I. Engel, et al., “Histamine as an Autocrine Growth Factor: An Unusual Role for a Widespread Mediator,” Seminars in Cancer Biology 10, no. 1 (2000): 15–23.

[341] C. A. Davio, G. P. Cricco, R. M. Bergoc, et al., “H1 and H2 Histamine Receptors in N-Nitroso-N-Methylurea (NMU)-Induced Carcinomas With Atypical Coupling to Signal Transducers,” Biochemical Pharmacology 50, no. 1 (1995): 91–96.

[342] V. Medina, M. Croci, E. Crescenti, et al., “The Role of Histamine in Human Mammary Carcinogenesis: H3 and H4 Receptors as Potential Therapeutic Targets for Breast Cancer Treatment,” Cancer Biology & Therapy 7, no. 1 (2008): 28–35.

[343] H. Hegyesi, B. Horváth, E. Pállinger, et al., “Histamine Elevates the Expression of Ets-1, a Protooncogen in Human Melanoma Cell Lines Through H2 Receptor,” FEBS Letters 579, no. 11 (2005): 2475–2479.

[344] G. Cricco, M. Núñez, V. Medina, et al., “Histamine Modulates Cellular Events Involved in Tumour Invasiveness in Pancreatic Carcinoma Cells,” Inflammation Research: Official Journal of the European Histamine Research Society 55 suppl. 1 (2006): S83–S84.

[345] G. Cricco, G. Martín, V. Medina, et al., “Histamine Inhibits Cell Proliferation and Modulates the Expression of Bcl-2 Family Proteins via the H2 Receptor in Human Pancreatic Cancer Cells,” Anticancer Research 26, no. 6B (2006): 4443–4450.

[346] H. Amano, K. Ando, S. Minamida, et al., “Adenylate Cyclase/Protein Kinase A Signaling Pathway Enhances Angiogenesis Through Induction of Vascular Endothelial Growth Factor In Vivo,” Japanese Journal of Pharmacology 87, no. 3 (2001): 181–188.

[347] F. Cianchi, C. Cortesini, N. Schiavone, et al., “The Role of Cyclooxygenase-2 in Mediating the Effects of Histamine on Cell Proliferation and Vascular Endothelial Growth Factor Production in Colorectal Cancer,” Clinical Cancer Research: An Official Journal of the American Association For Cancer Research 11, no. 19 pt. 1 (2005): 6807–6815.

[348] X. D. Yang, W. Ai, S. Asfaha, et al., “Histamine Deficiency Promotes Inflammation-Associated Carcinogenesis Through Reduced Myeloid Maturation and Accumulation of CD11b+Ly6G+ Immature Myeloid Cells,” Nature Medicine 17, no. 1 (2011): 87–95.

[349] M. A. Kuefner, H. G. Schwelberger, E. G. Hahn, et al., “Decreased Histamine Catabolism in the Colonic Mucosa of Patients With Colonic Adenoma,” Digestive Diseases and Sciences 53, no. 2 (2008): 436–442.

[350] K. Tomita and S. Okabe, “Exogenous Histamine Stimulates Colorectal Cancer Implant Growth via Immunosuppression in Mice,” Journal of Pharmacological Sciences 97, no. 1 (2005): 116–123.

[351] K. Dib, T. Perecko, V. Jenei, et al., “The Histamine H4 Receptor Is a Potent Inhibitor of Adhesion-Dependent Degranulation in Human Neutrophils,” Journal of Leukocyte Biology 96, no. 3 (2014): 411–418.

[352] S. F. Ahmad, K. M. A. Zoheir, M. A. Ansari, et al., “Stimulation of the Histamine 4 Receptor With 4-Methylhistamine Modulates the Effects of Chronic Stress on the Th1/Th2 Cytokine Balance,” Immunobiology 220, no. 3 (2015): 341–349.

[353] M. Dohlsten, H. O. Sjögren, and R. Carlsson, “Histamine Acts Directly on Human T Cells to Inhibit Interleukin-2 and Interferon-Gamma Production,” Cellular Immunology 109, no. 1 (1987): 65–74.

[354] K. Takahashi, S. Tanaka, and A. Ichikawa, “Effect of Cimetidine on Intratumoral Cytokine Expression in an Experimental Tumor,” Biochemical and Biophysical Research Communications 281, no. 5 (2001): 1113–1119.

[355] D. J. Martinel Lamas, M. Croci, E. Carabajal, et al., “Therapeutic Potential of Histamine H₄ Receptor Agonists in Triple-Negative Human Breast Cancer Experimental Model,” British Journal of Pharmacology 170, no. 1 (2013): 188–199.

[356] D. J. Martinel Lamas, E. S. Rivera, and V. A. Medina, “Histamine H4 Receptor: Insights Into a Potential Therapeutic Target in Breast Cancer,” Frontiers in Bioscience (Scholar Edition) 7, no. 1 (2015): 1–9.

[357] A. Martner, H. G. Wiktorin, B. Lenox, et al., “Histamine Promotes the Development of Monocyte-Derived Dendritic Cells and Reduces Tumor Growth by Targeting the Myeloid NADPH Oxidase,” Journal of Immunology (Baltimore, Md) 194, no. 10 (2015): 5014–5021.

[358] J. O. Rinne, O. V. Anichtchik, K. S. Eriksson, et al., “Increased Brain Histamine Levels in Parkinson's Disease but not in Multiple System Atrophy,” Journal of Neurochemistry 81, no. 5 (2002): 954–960.

[359] P. Nowak, A. Bortel, J. Dabrowska, et al., “Histamine H(3) Receptor Ligands Modulate L-DOPA-Evoked Behavioral Responses and L-DOPA Derived Extracellular Dopamine in Dopamine-Denervated Rat Striatum,” Neurotoxicity Research 13, no. 3–4 (2008): 231–240.

[360] L. C. Baldan, K. A. Williams, J. Gallezot, et al., “Histidine Decarboxylase Deficiency Causes Tourette Syndrome: Parallel Findings in Humans and Mice,” Neuron 81, no. 1 (2014): 77–90.

[361] C. Ferrada, E. Moreno, V. Casadó, et al., “Marked Changes in Signal Transduction Upon Heteromerization of Dopamine D1 and Histamine H3 Receptors,” British Journal of Pharmacology 157, no. 1 (2009): 64–75.

[362] E. Moreno, H. Hoffmann, M. Gonzalez-Sepúlveda, et al., “Dopamine D1-Histamine H3 Receptor Heteromers Provide a Selective Link to MAPK Signaling in GABAergic Neurons of the Direct Striatal Pathway,” Journal of Biological Chemistry 286, no. 7 (2011): 5846–5854.

[363] L. Shan, K. Bossers, S. Luchetti, et al., “Alterations in the Histaminergic System in the Substantia Nigra and Striatum of Parkinson's Patients: A Postmortem Study,” Neurobiology of Aging 33, no. 7 (2012): 1488.e1481–1488.1413.

[364] S. A. Liddelow, K. A. Guttenplan, L. E. Clarke, et al., “Neurotoxic Reactive Astrocytes Are Induced by Activated Microglia,” Nature 541, no. 7638 (2017): 481–487.

[365] M. S. Moehle and A. B. West, “M1 and M2 Immune Activation in Parkinson's Disease: Foe and Ally?” Neuroscience 302 (2015): 59–73.

[366] H. Kabata and D. Artis, “Neuro-Immune Crosstalk and Allergic Inflammation,” Journal of Clinical Investigation 129, no. 4 (2019): 1475–1482.

[367] T. Ahmed, K. B. Mirbahar, W. Oliver, et al., “Characterization of H1- and H2-Receptor Function in Pulmonary and Systemic Circulations of Sheep,” Journal of Applied Physiology: Respiratory, Environmental and Exercise Physiology 53, no. 1 (1982): 175–184.

[368] M. V. White, “The Role of Histamine in Allergic Diseases,” Journal of Allergy and Clinical Immunology 86, no. 4 pt. 2 (1990): 599–605.

[369] M. Jutel, T. Watanabe, S. Klunker, et al., “Histamine Regulates T-Cell and Antibody Responses by Differential Expression of H1 and H2 Receptors,” Nature 413, no. 6854 (2001): 420–425.

[370] K. Yamauchi and M. Ogasawara, “The Role of Histamine in the Pathophysiology of Asthma and the Clinical Efficacy of Antihistamines in Asthma Therapy,” International Journal of Molecular Sciences 20, no. 7 (2019): 1733.

[371] A. Roquet, B. Dahlén, M. Kumlin, et al., “Combined Antagonism of Leukotrienes and Histamine Produces Predominant Inhibition of Allergen-Induced Early and Late Phase Airway Obstruction in Asthmatics,” American Journal of Respiratory and Critical Care Medicine 155, no. 6 (1997): 1856–1863.

[372] M. O'Reilly, R. Alpert, S. Jenkinson, et al., “Identification of a Histamine H4 Receptor on Human Eosinophils–Role in Eosinophil Chemotaxis,” Journal of Receptor and Signal Transduction Research 22, no. 1–4 (2002): 431–448.

[373] D. Neumann, S. Beermann, and R. Seifert, “Does the Histamine H4 Receptor Have a Pro- or Anti-Inflammatory Role in Murine Bronchial Asthma?” Pharmacology 85, no. 4 (2010): 217–223.

[374] L. J. Kay, S. K. Suvarna, and P. T. Peachell, “Histamine H4 Receptor Mediates Chemotaxis of Human Lung Mast Cells,” European Journal of Pharmacology 837 (2018): 38–44.

[375] C. L. Hofstra, P. J. Desai, R. L. Thurmond, et al., “Histamine H4 Receptor Mediates Chemotaxis and Calcium Mobilization of Mast Cells,” Journal of Pharmacology and Experimental Therapeutics 305, no. 3 (2003): 1212–1221.

[376] I. Villanueva, M. Piñón, L. Quevedo-Corona, et al., “Epinephrine and Dopamine Colocalization With Norepinephrine in Various Peripheral Tissues: Guanethidine Effects,” Life Sciences 73, no. 13 (2003): 1645–1653.

[377] C. Missale, S. R. Nash, S. W. Robinson, et al., “Dopamine Receptors: From Structure to Function,” Physiological Reviews 78, no. 1 (1998): 189–225.

[378] P. Barbanti, G. Fabbrini, A. Ricci, et al., “Reduced Density of Dopamine D2-Like Receptors on Peripheral Blood Lymphocytes in Alzheimer's Disease,” Mechanisms of Ageing and Development 120, no. 1–3 (2000): 65–75.

[379] P. Barbanti, G. Fabbrini, A. Ricci, et al., “Increased Expression of Dopamine Receptors on Lymphocytes in Parkinson's Disease,” Movement Disorders: Official Journal of the Movement Disorder Society 14, no. 5 (1999): 764–771.

[380] P. Barbanti, G. Fabbrini, A. Ricci, et al., “Migraine Patients Show an Increased Density of Dopamine D3 and D4 Receptors on Lymphocytes,” Cephalalgia: An International Journal of Headache 20, no. 1 (2000): 15–19.

[381] M. Giorelli, P. Livrea, and M. Trojano, “Dopamine Fails to Regulate Activation of Peripheral Blood Lymphocytes From Multiple Sclerosis Patients: Effects of IFN-Beta,” Journal of Interferon & Cytokine Research: The Official Journal of the International Society for Interferon and Cytokine Research 25, no. 7 (2005): 395–406.

[382] T. Ilani, D. Ben-Shachar, R. D. Strous, et al., “A Peripheral Marker for Schizophrenia: Increased Levels of D3 Dopamine Receptor mRNA in Blood Lymphocytes,” Proceedings of the National Academy of Sciences of the United States of America 98, no. 2 (2001): 625–628.

[383] M. Mancino, E. Ametller, P. Gascón, et al., “The Neuronal Influence on Tumor Progression,” Biochimica et Biophysica Acta 1816, no. 2 (2011): 105–118.

[384] J. Beaulieu and R. R. Gainetdinov, “The Physiology, Signaling, and Pharmacology of Dopamine Receptors,” Pharmacological Reviews 63, no. 1 (2011): 182–217.

[385] C. Rangel-Barajas, I. Coronel, and B. Florán, “Dopamine Receptors and Neurodegeneration,” Aging and Disease 6, no. 5 (2015): 349–368.

[386] B. Channer, S. M. Matt, E. A. Nickoloff-Bybel, et al., “Dopamine, Immunity, and Disease,” Pharmacological Reviews 75, no. 1 (2023): 62–158.

[387] X. Wang, Z. Wang, C. Luo, et al., “The Prospective Value of Dopamine Receptors on Bio-Behavior of Tumor,” Journal of Cancer 10, no. 7 (2019): 1622–1632.

[388] X. Qian, D. Zhang, Z. Cao, et al., “Dopamine Pathway Mediated by DRD5 Facilitates Tumor Growth via Enhancing Warburg Effect in Esophageal Cancer,” Frontiers in Oncology 11 (2021): 655861.

[389] S. Ganguly, B. Basu, S. Shome, et al., “Dopamine, by Acting Through Its D2 Receptor, Inhibits Insulin-Like Growth Factor-I (IGF-I)-Induced Gastric Cancer Cell Proliferation via Up-Regulation of Krüppel-Like Factor 4 Through Down-Regulation of IGF-IR and AKT Phosphorylation,” American Journal of Pathology 177, no. 6 (2010): 2701–2707.

[390] D. C. Borcherding, W. Tong, E. R. Hugo, et al., “Expression and Therapeutic Targeting of Dopamine Receptor-1 (D1R) in Breast Cancer,” Oncogene 35, no. 24 (2016): 3103–3113.

[391] C. V. Clevenger, W. P. Chang, W. Ngo, et al., “Expression of Prolactin and Prolactin Receptor in Human Breast Carcinoma. Evidence for an Autocrine/Paracrine Loop,” American Journal of Pathology 146, no. 3 (1995): 695–705.

[392] Y. Tan, R. Sun, L. Liu, et al., “Tumor Suppressor DRD2 Facilitates M1 Macrophages and Restricts NF-κB Signaling to Trigger Pyroptosis in Breast Cancer,” Theranostics 11, no. 11 (2021): 5214–5231.

[393] Y. Yan, J. Pan, Y. Chen, et al., “Increased Dopamine and Its Receptor Dopamine Receptor D1 Promote Tumor Growth in Human Hepatocellular Carcinoma,” Cancer Communications (London) 40, no. 12 (2020): 694–710.

[394] M. Lu, J. Li, Z. Luo, et al., “Roles of Dopamine Receptors and Their Antagonist Thioridazine in Hepatoma Metastasis,” Onco Targets Therapy 8 (2015): 1543–1552.

[395] J. Gao, C. Zhang, F. Gao, et al., “The Effect and Mechanism of Dopamine D1 Receptors on the Proliferation of Osteosarcoma Cells,” Molecular and Cellular Biochemistry 430, no. 1–2 (2017): 31–36.

[396] H. Lee, S. Shim, J. S. Kong, et al., “Overexpression of Dopamine Receptor D2 Promotes Colorectal Cancer Progression by Activating the β-Catenin/ZEB1 Axis,” Cancer Science 112, no. 9 (2021): 3732–3743.

[397] Z. G. Leng, S. J. Lin, Z. R. Wu, et al., “Activation of DRD5 (Dopamine Receptor D5) Inhibits Tumor Growth by Autophagic Cell Death,” Autophagy 13, no. 8 (2017): 1404–1419.

[398] P. Sobczuk, M. Łomiak, and A. Cudnoch-Jędrzejewska, “Dopamine D1 Receptor in Cancer,” Cancers 12, no. 11 (2020): 3232.

[399] S. A. Treseder, L. A. Smith, and P. Jenner, “Endogenous Dopaminergic Tone and Dopamine Agonist Action,” Movement Disorders: Official Journal of the Movement Disorder Society 15, no. 5 (2000): 804–812.

[400] P. Sobczuk, M. Łomiak, and A. Cudnoch-Jędrzejewska, “Dopamine D1 Receptor in Cancer,” Cancers (Basel) 12, no. 11 (2020): 3232.

[401] D. Chakroborty, C. Sarkar, B. Basu, et al., “Catecholamines Regulate Tumor Angiogenesis,” Cancer Research 69, no. 9 (2009): 3727–3730.

[402] S. Basu, C. Sarkar, D. Chakroborty, et al., “Ablation of Peripheral Dopaminergic Nerves Stimulates Malignant Tumor Growth by Inducing Vascular Permeability Factor/Vascular Endothelial Growth Factor-Mediated Angiogenesis,” Cancer Research 64, no. 16 (2004): 5551–5555.

[403] L. H. Hoeppner, Y. Wang, A. Sharma, et al., “Dopamine D2 Receptor Agonists Inhibit Lung Cancer Progression by Reducing Angiogenesis and Tumor Infiltrating Myeloid Derived Suppressor Cells,” Molecular Oncology 9, no. 1 (2015): 270–281.

[404] D. Chakroborty, U. R. Chowdhury, C. Sarkar, et al., “Dopamine Regulates Endothelial Progenitor Cell Mobilization From Mouse Bone Marrow in Tumor Vascularization,” Journal of Clinical Investigation 118, no. 4 (2008): 1380–1389.

[405] S. Basu, J. A. Nagy, S. Pal, et al., “The Neurotransmitter Dopamine Inhibits Angiogenesis Induced by Vascular Permeability Factor/Vascular Endothelial Growth Factor,” Nature Medicine 7, no. 5 (2001): 569–574.

[406] M. Moreno-Smith, C. Lu, M. M. K. Shahzad, et al., “Dopamine Blocks Stress-Mediated Ovarian Carcinoma Growth,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 17, no. 11 (2011): 3649–3659.

[407] Y. Zhou, J. Tang, M. Weng, et al., “DRD4 Interacts With TGF-β Receptors to Drive Colorectal Cancer Metastasis Independently of Dopamine Signaling Pathway,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 12, no. 6 (2024): e2413953.

[408] M. Pinoli, F. Marino, and M. Cosentino, “Dopaminergic Regulation of Innate Immunity: A Review,” Journal of Neuroimmune Pharmacology: The Official Journal of the Society on NeuroImmune Pharmacology 12, no. 4 (2017): 602–623.

[409] C. Sarkar, B. Basu, D. Chakroborty, et al., “The Immunoregulatory Role of Dopamine: An Update,” Brain, Behavior, and Immunity 24, no. 4 (2010): 525–528.

[410] M. Levite, “Dopamine and T Cells: Dopamine Receptors and Potent Effects on T Cells, Dopamine Production in T Cells, and Abnormalities in the Dopaminergic System in T Cells in Autoimmune, Neurological and Psychiatric Diseases,” Acta Physiologica (Oxford, England) 216, no. 1 (2016): 42–89.

[411] B. Saha, A. C. Mondal, S. Basu, et al., “Circulating Dopamine Level, in Lung Carcinoma Patients, Inhibits Proliferation and Cytotoxicity of CD4+ and CD8+ T Cells by D1 Dopamine Receptors: An In Vitro Analysis,” International Immunopharmacology 1, no. 7 (2001): 1363–1374.

[412] Y. Wu, L. Zhu, S. Li, et al., “DA-DRD5 Signaling Reprograms B Cells to Promote CD8+ T Cell-Mediated Antitumor Immunity,” Cell Reports 44, no. 3 (2025): 115364.

[413] X. Wang, Z. B. Wang, C. Luo, et al., “The Prospective Value of Dopamine Receptors on Bio-Behavior of Tumor,” Journal of Cancer 10, no. 7 (2019): 1622–1632.

[414] J. Wu, R. Zhang, N. Tang, et al., “Dopamine Inhibits the Function of Gr-1+CD115+ Myeloid-Derived Suppressor Cells Through D1-Like Receptors and Enhances Anti-Tumor Immunity,” Journal of Leukocyte Biology 97, no. 1 (2015): 191–200.

[415] M. Cosentino, A. M. Fietta, M. Ferrari, et al., “Human CD4+CD25+ Regulatory T Cells Selectively Express Tyrosine Hydroxylase and Contain Endogenous Catecholamines Subserving an Autocrine/Paracrine Inhibitory Functional Loop,” Blood 109, no. 2 (2007): 632–642.

[416] E. L. Leung, J. Huang, J. Zhang, et al., “Novel Anticancer Strategy by Targeting the Gut Microbial Neurotransmitter Signaling to Overcome Immunotherapy Resistance,” Antioxidants & Redox Signaling 38, no. 4–6 (2023): 298–315.

[417] Q. Liu, R. Zhang, X. Zhang, et al., “Dopamine Improves Chemotherapeutic Efficacy for Pancreatic Cancer by Regulating Macrophage-Derived Inflammations,” Cancer Immunology, Immunotherapy: CII 70, no. 8 (2021): 2165–2177.

[418] G. Li, Y. Jiang, H. Tong, et al., “Sciatic Nerve Stimulation Enhances NK Cell Cytotoxicity Through Dopamine Signaling and Synergizes Immunotherapy in Triple-Negative Breast Cancer,” Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy 79 (2025): 101212.

[419] J. D. Salamone and M. Correa, “The Mysterious Motivational Functions of Mesolimbic Dopamine,” Neuron 76, no. 3 (2012): 470–485.

[420] H. Braak, K. Del Tredici, U. Rüb, et al., “Staging of Brain Pathology Related to Sporadic Parkinson's Disease,” Neurobiology of Aging 24, no. 2 (2003): 197–211.

[421] Ü. Ö. Akdemir, A. Bora Tokçaer, and L. Ö. Atay, “Dopamine Transporter SPECT Imaging in Parkinson's Disease and Parkinsonian Disorders,” Turkish Journal of Medical Sciences 51, no. 2 (2021): 400–410.

[422] M. R. DeLong, “Primate Models of Movement Disorders of Basal Ganglia Origin,” Trends in Neurosciences 13, no. 7 (1990): 281–285.

[423] K. R. Chaudhuri, D. G. Healy, and A. H. V. Schapira, “Non-Motor Symptoms of Parkinson's Disease: Diagnosis and Management,” Lancet Neurology 5, no. 3 (2006): 235–245.

[424] M. Naoi, W. Maruyama, M. Shamoto-Nagai, et al., “Toxic Interactions Between Dopamine, α-Synuclein, Monoamine Oxidase, and Genes in Mitochondria of Parkinson's Disease,” Journal of Neural Transmission (Vienna, Austria: 1996) 131, no. 6 (2024): 639–661.

[425] O. Weinreb, T. Amit, P. Riederer, et al., “Neuroprotective Profile of the Multitarget Drug Rasagiline in Parkinson's Disease,” International Review of Neurobiology 100 (2011): 127–149.

[426] J. Segura-Aguilar, I. Paris, P. Muñoz, et al., “Protective and Toxic Roles of Dopamine in Parkinson's Disease,” Journal of Neurochemistry 129, no. 6 (2014): 898–915.

[427] R. Gordon, E. A. Albornoz, D. C. Christie, et al., “Inflammasome Inhibition Prevents α-Synuclein Pathology and Dopaminergic Neurodegeneration in Mice,” Science Translational Medicine 10, no. 465 (2018): eaah4066.

[428] A. Kouli, M. Camacho, K. Allinson, et al., “Neuroinflammation and Protein Pathology in Parkinson's Disease Dementia,” Acta Neuropathologica Communications 8, no. 1 (2020): 211.

[429] L. Sun, W. Jiang, Y. Wang, et al., “Phosphorylated α-Synuclein Aggregated in Schwann Cells Exacerbates Peripheral Neuroinflammation and Nerve Dysfunction in Parkinson's Disease Through TLR2/NF-κB Pathway,” Cell Death Discovery 7, no. 1 (2021): 289.

[430] O. Scudamore and T. Ciossek, “Increased Oxidative Stress Exacerbates α-Synuclein Aggregation In Vivo,” Journal of Neuropathology and Experimental Neurology 77, no. 6 (2018): 443–453.

[431] E. Lee, I. Hwang, S. Park, et al., “MPTP-Driven NLRP3 Inflammasome Activation in Microglia Plays a Central Role in Dopaminergic Neurodegeneration,” Cell Death and Differentiation 26, no. 2 (2019): 213–228.

[432] K. Guzmán-Ramos, D. Osorio-Gómez, and F. Bermúdez-Rattoni, “Cognitive Impairment in Alzheimer's and Metabolic Diseases: A Catecholaminergic Hypothesis,” Neuroscience 497 (2022): 308–323.

[433] R. A. Mitchell, N. Herrmann, and K. L. Lanctôt, “The Role of Dopamine in Symptoms and Treatment of Apathy in Alzheimer's Disease,” CNS Neuroscience & Therapeutics 17, no. 5 (2011): 411–427.

[434] K. T. Chang and D. K. Berg, “Voltage-Gated Channels Block Nicotinic Regulation of CREB Phosphorylation and Gene Expression in Neurons,” Neuron 32, no. 5 (2001): 855–865.

[435] M. Hu, L. Q-s, K. T. Chang, et al., “Nicotinic Regulation of CREB Activation in Hippocampal Neurons by Glutamatergic and Nonglutamatergic Pathways,” Molecular and Cellular Neurosciences 21, no. 4 (2002): 616–625.

[436] Y. Tanaka, K. Meguro, S. Yamaguchi, et al., “Decreased Striatal D2 Receptor Density Associated With Severe Behavioral Abnormality in Alzheimer's Disease,” Annals of Nuclear Medicine 17, no. 7 (2003): 567–573.

[437] N. Kemppainen, H. Ruottinen, K. Nâgren, et al., “PET Shows That Striatal Dopamine D1 and D2 Receptors Are Differentially Affected in AD,” Neurology 55, no. 2 (2000): 205–209.

[438] A. L. Pritchard, L. Ratcliffe, E. Sorour, et al., “Investigation of Dopamine Receptors in Susceptibility to Behavioural and Psychological Symptoms in Alzheimer's Disease,” International Journal of Geriatric Psychiatry 24, no. 9 (2009): 1020–1025.

[439] M. Kurnik-Łucka, P. Pasieka, P. Łączak, et al., “Gastrointestinal Dopamine in Inflammatory Bowel Diseases: A Systematic Review,” International Journal of Molecular Sciences 22, no. 23 (2021): 12932.

[440] A. Sclafani, “Post-Ingestive Positive Controls of Ingestive Behavior,” Appetite 36, no. 1 (2001): 79–83.

[441] R. H. Straub, F. Grum, U. Strauch, et al., “Anti-Inflammatory Role of Sympathetic Nerves in Chronic Intestinal Inflammation,” Gut 57, no. 7 (2008): 911–921.

[442] G. Tolstanova, X. Deng, A. Ahluwalia, et al., “Role of Dopamine and D2 Dopamine Receptor in the Pathogenesis of Inflammatory Bowel Disease,” Digestive Diseases and Sciences 60, no. 10 (2015): 2963–2975.

[443] T. Miyazawa, M. Matsumoto, S. Kato, et al., “Dopamine-Induced Protection Against Indomethacin-Evoked Intestinal Lesions in Rats—Role of Anti-Intestinal Motility Mediated by D2 Receptors,” Medical Science Monitor: International Medical Journal of Experimental and Clinical Research 9, no. 2 (2003): BR71–BR77.

[444] M. G. Zizzo, A. Bellanca, A. Amato, et al., “Opposite Effects of Dopamine on the Mechanical Activity of Circular and Longitudinal Muscle of Human Colon,” Neurogastroenterology and Motility 32, no. 6 (2020): e13811.

[445] R. Serio and M. G. Zizzo, “The Multiple Roles of Dopamine Receptor Activation in the Modulation of Gastrointestinal Motility and Mucosal Function,” Autonomic Neuroscience: Basic & Clinical 244 (2023): 103041.

[446] F. Contreras, C. Prado, H. González, et al., “Dopamine Receptor D3 Signaling on CD4+ T Cells Favors Th1- and Th17-Mediated Immunity,” Journal of Immunology (Baltimore, Md) 196, no. 10 (2016): 4143–4149.

[447] M. P. C. Ribeiro, J. B. A. Custódio, and A. E. Santos, “Ionotropic Glutamate Receptor Antagonists and Cancer Therapy: Time to Think Out of the Box?” Cancer Chemotherapy and Pharmacology 79, no. 2 (2017): 219–225.

[448] O. A. C. Petroff, “GABA and Flutamate in the Human Brain,” Neuroscientist: A Review Journal Bringing Neurobiology, Neurology and Psychiatry 8, no. 6 (2002): 562–573.

[449] M. Nedergaard, T. Takano, and A. J. Hansen, “Beyond the Role of Glutamate as a Neurotransmitter,” Nature Reviews Neuroscience 3, no. 9 (2002): 748–755.

[450] A. C. Foster and J. A. Kemp, “Glutamate- and GABA-Based CNS Therapeutics,” Current Opinion in Pharmacology 6, no. 1 (2006): 7–17.

[451] P. Gaudreau, B. Allard, M. Turcotte, et al., “CD73-Adenosine Reduces Immune Responses and Survival in Ovarian Cancer Patients,” Oncoimmunology 5, no. 5 (2016): e1127496.

[452] S. S. Willard and S. Koochekpour, “Glutamate, Glutamate Receptors, and Downstream Signaling Pathways,” International Journal of Biological Sciences 9, no. 9 (2013): 948–959.

[453] R. Lujan, Z. Nusser, J. D. Roberts, et al., “Perisynaptic Location of Metabotropic Glutamate Receptors mGluR1 and mGluR5 on Dendrites and Dendritic Spines in the Rat Hippocampus,” European Journal of Neuroscience 8, no. 7 (1996): 1488–1500.

[454] B. S. Meldrum, “Glutamate as a Neurotransmitter in the Brain: Review of Physiology and Pathology,” Journal of Nutrition 130, no. 4S suppl. (2000): 1007S–1015S.

[455] R. Shigemoto, A. Kulik, J. D. Roberts, et al., “Target-Cell-Specific Concentration of a Metabotropic Glutamate Receptor in the Presynaptic Active Zone,” Nature 381, no. 6582 (1996): 523–525.

[456] Y. Kanai and M. A. Hediger, “Primary Structure and Functional Characterization of a High-Affinity Glutamate Transporter,” Nature 360, no. 6403 (1992): 467–471.

[457] J. Lewerenz, S. J. Hewett, Y. Huang, et al., “The Cystine/Glutamate Antiporter System x(c)(-) in Health and Disease: From Molecular Mechanisms to Novel Therapeutic Opportunities,” Antioxidants & Redox Signaling 18, no. 5 (2013): 522–555.

[458] H. Yi, G. Talmon, and J. Wang, “Glutamate in Cancers: From Metabolism to Signaling,” Journal of Biomedical Research 34, no. 4 (2019): 260–270.

[459] R. J. Bridges, N. R. Natale, and S. A. Patel, “System xc⁻ Cystine/Glutamate Antiporter: An Update on Molecular Pharmacology and Roles Within the CNS,” British Journal of Pharmacology 165, no. 1 (2012): 20–34.

[460] J. F. de Groot, T. J. Liu, G. Fuller, et al., “The Excitatory Amino Acid Transporter-2 Induces Apoptosis and Decreases Glioma Growth In Vitro and In Vivo,” Cancer Research 65, no. 5 (2005): 1934–1940.

[461] K. J. Briggs, P. Koivunen, S. Cao, et al., “Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine,” Cell 166, no. 1 (2016): 126–139.

[462] M. Banda, C. L. Speyer, S. N. Semma, et al., “Metabotropic Glutamate Receptor-1 Contributes to Progression in Triple Negative Breast Cancer,” PLoS ONE 9, no. 1 (2014): e81126.

[463] C. L. Speyer, M. A. Bukhsh, W. S. Jafry, et al., “Riluzole Synergizes With Paclitaxel to Inhibit Cell Growth and Induce Apoptosis in Triple-Negative Breast Cancer,” Breast Cancer Research and Treatment 166, no. 2 (2017): 407–419.

[464] L. Palamiuc and B. M. Emerling, “PSMA Brings New Flavors to PI3K Signaling: A Role for Glutamate in Prostate Cancer,” Journal of Experimental Medicine 215, no. 1 (2018): 17–19.

[465] S. Koochekpour, S. Majumdar, G. Azabdaftari, et al., “Serum Glutamate Levels Correlate With Gleason Score and Glutamate Blockade Decreases Proliferation, Migration, and Invasion and Induces Apoptosis in Prostate Cancer Cells,” Clinical Cancer Research 18, no. 21 (2012): 5888–5901.

[466] Y. Wen, J. Li, J. Koo, et al., “Activation of the Glutamate Receptor GRM1 Enhances Angiogenic Signaling to Drive Melanoma Progression,” Cancer Research 74, no. 9 (2014): 2499–2509.

[467] L. J. Yu, B. A. Wall, J. Wangari-Talbot, et al., “Metabotropic Glutamate Receptors in Cancer,” Neuropharmacology 115 (2017): 193–202.

[468] L. Zhao, P. Liu, A. Sauvat, et al., “Dexmedetomidine Induces Immunogenic Cancer Cell Death and Sensitizes Tumors to PD-1 Blockade,” Journal for Immunotherapy of Cancer 13, no. 6 (2025): e010714.

[469] W. Rzeski, C. Ikonomidou, and L. Turski, “Glutamate Antagonists Limit Tumor Growth,” Biochemical Pharmacology 64, no. 8 (2002): 1195–1200.

[470] D. S. Ruiz, H. Luksch, M. Sifringer, et al., “AMPA Receptor Antagonist CFM-2 Decreases Survivin Expression in Cancer Cells,” Anti-Cancer Agents in Medicinal Chemistry 18, no. 4 (2018): 591–596.

[471] H. J. Chang, B. C. Yoo, S. Lim, et al., “Metabotropic Glutamate Receptor 4 Expression in Colorectal Carcinoma and Its Prognostic Significance,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 11, no. 9 (2005): 3288–3295.

[472] B. C. Yoo, E. Jeon, S. Hong, et al., “Metabotropic Glutamate Receptor 4-Mediated 5-Fluorouracil Resistance in a Human Colon Cancer Cell Line,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 10, no. 12 Pt 1 (2004): 4176–4184.

[473] B. Xiao, D. Chen, Q. Zhou, et al., “Glutamate Metabotropic Receptor 4 (GRM4) Inhibits Cell Proliferation, Migration and Invasion in Breast Cancer and Is Regulated by miR-328-3p and miR-370-3p,” BMC Cancer 19, no. 1 (2019): 891.

[474] A. Herner, D. Sauliunaite, C. W. Michalski, et al., “Glutamate Increases Pancreatic Cancer Cell Invasion and Migration via AMPA Receptor Activation and Kras-MAPK Signaling,” International Journal of Cancer 129, no. 10 (2011): 2349–2359.

[475] S. A. Lyons, W. J. Chung, A. K. Weaver, et al., “Autocrine Glutamate Signaling Promotes Glioma Cell Invasion,” Cancer Research 67, no. 19 (2007): 9463–9471.

[476] K. S. Brocke, C. Staufner, H. Luksch, et al., “Glutamate Receptors in Pediatric Tumors of the Central Nervous System,” Cancer Biology & Therapy 9, no. 6 (2010): 455–468.

[477] P. Jonas, C. Racca, B. Sakmann, et al., “Differences in Ca²⁺ Permeability of AMPA-Type Glutamate Receptor Channels in Neocortical Neurons Caused by Differential GluR-B Subunit Expression,” Neuron 12, no. 6 (1994): 1281–1289.

[478] J. H. Uhm, C. L. Gladson, and J. S. Rao, “The Role of Integrins in the Malignant Phenotype of Gliomas,” Frontiers in Bioscience: A Journal and Virtual Library 4 (1999): D188–D199.

[479] F. Li, C. He, H. Yao, et al., “Glutamate From Nerve Cells Promotes Perineural Invasion in Pancreatic Cancer by Regulating Tumor Glycolysis Through HK2 mRNA-m6A Modification,” Pharmacological Research 187 (2023): 106555.

[480] Q. Huang, B. Hu, P. Zhang, et al., “Neuroscience of Cancer: Unraveling the Complex Interplay Between the Nervous System, the Tumor and the Tumor Immune Microenvironment,” Molecular Cancer 24, no. 1 (2025): 24.

[481] S. Koochekpour, “Glutamate, a Metabolic Biomarker of Aggressiveness and a Potential Therapeutic Target for Prostate Cancer,” Asian Journal of Andrology 15, no. 2 (2013): 212–213.

[482] K. Ishibashi, T. Ichinose, R. Kadokawa, et al., “Astrocyte-Induced mGluR1 Activates Human Lung Cancer Brain Metastasis via Glutamate-Dependent Stabilization of EGFR,” Developmental Cell 59, no. 5 (2024): 579–594.

[483] A. E. M. Bastiaansen, A. M. Timmermans, M. Smid, et al., “Metabotropic Glutamate Receptor 1 Is Associated With Unfavorable Prognosis in ER-Negative and Triple-Negative Breast Cancer,” Scientific Reports 10, no. 1 (2020): 22292.

[484] R. Q. Li, X. H. Zhao, Q. Zhu, et al., “Exploring Neurotransmitters and Their Receptors for Breast Cancer Prevention and Treatment,” Theranostics 13, no. 3 (2023): 1109–1129.

[485] L. Iacovelli, A. Arcella, G. Battaglia, et al., “Pharmacological Activation of mGlu4 Metabotropic Glutamate Receptors Inhibits the Growth of Medulloblastomas,” Journal of Neuroscience: The Official Journal of the Society for Neuroscience 26, no. 32 (2006): 8388–8397.

[486] A. A. Boldyrev, E. A. Bryushkova, and E. A. Vladychenskaya, “NMDA Receptors in Immune Competent Cells,” Biochemistry Biokhimiia 77, no. 2 (2012): 128–134.

[487] Y. Ganor and M. Levite, “The Neurotransmitter Glutamate and Human T Cells: Glutamate Receptors and Glutamate-Induced Direct and Potent Effects on Normal Human T Cells, Cancerous Human Leukemia and Lymphoma T Cells, and Autoimmune Human T Cells,” Journal of Neural Transmission (Vienna, Austria: 1996) 121, no. 8 (2014): 983–1006.

[488] E. Vladychenskaya, O. Tyulina, S. Urano, et al., “Rat Lymphocytes Express NMDA Receptors That Take Part in Regulation of Cytokine Production,” Cell Biochemistry and Function 29, no. 7 (2011): 527–533.

[489] H. Xue and C. J. Field, “New Role of Glutamate as an Immunoregulator via Glutamate Receptors and Transporters,” Frontiers in Bioscience (Scholar Edition) 3, no. 3 (2011): 1007–1020.

[490] K. Orihara, S. O. Odemuyiwa, W. P. Stefura, et al., “Neurotransmitter Signalling via NMDA Receptors Leads to Decreased T Helper Type 1-Like and Enhanced T Helper Type 2-Like Immune Balance in Humans,” Immunology 153, no. 3 (2018): 368–379.

[491] T. Xiong, P. He, M. Zhou, et al., “Glutamate Blunts Cell-Killing Effects of Neutrophils in Tumor Microenvironment,” Cancer Science 113, no. 6 (2022): 1955–1967.

[492] S. Koda, J. Hu, X. Ju, et al., “The Role of Glutamate Receptors in the Regulation of the Tumor Microenvironment,” Frontiers in Immunology 14 (2023): 1123841.

[493] R. E. Sexton, A. H. Hachem, A. A. Assi, et al., “Metabotropic Glutamate Receptor-1 Regulates Inflammation in Triple Negative Breast Cancer,” Scientific Reports 8, no. 1 (2018): 16008.

[494] Z. Wan, R. Sun, Y. Liu, et al., “Targeting Metabotropic Glutamate Receptor 4 for Cancer Immunotherapy,” Science Advances 7, no. 50 (2021): eabj4226.

[495] L. Iovino, M. E. Tremblay, and L. Civiero, “Glutamate-Induced Excitotoxicity in Parkinson's Disease: The Role of Glial Cells,” Journal of Pharmacological Sciences 144, no. 3 (2020): 151–164.

[496] Y. Zhang, X. Zhang, and S. Qu, “Ceftriaxone Protects Astrocytes from MPP(+) via Suppression of NF-κB/JNK/c-Jun Signaling,” Molecular Neurobiology 52, no. 1 (2015): 78–92.

[497] Y. Zhang, X. He, X. Meng, et al., “Regulation of Glutamate Transporter Trafficking by Nedd4-2 in a Parkinson's Disease Model,” Cell Death & Disease 8, no. 2 (2017): e2574.

[498] X. Wu, X. Meng, F. Tan, et al., “Regulatory Mechanism of miR-543-3p on GLT-1 in a Mouse Model of Parkinson's Disease,” ACS Chemical Neuroscience 10, no. 3 (2019): 1791–1800.

[499] D. Wu, S. Wang, X. Wen, et al., “Suppression of MicroRNA-342-3p Increases Glutamate Transporters and Prevents Dopaminergic Neuron Loss Through Activating the Wnt Signaling Pathway via p21-Activated Kinase 1 in Mice With Parkinson's Disease,” Journal of Cellular Physiology 234, no. 6 (2019): 9033–9044.

[500] P. J. Conn, G. Battaglia, M. J. Marino, et al., “Metabotropic Glutamate Receptors in the Basal Ganglia Motor Circuit,” Nature Reviews Neuroscience 6, no. 10 (2005): 787–798.

[501] N. Jonkers, S. Sarre, G. Ebinger, et al., “MK801 Suppresses the L-DOPA-Induced Increase of Glutamate in Striatum of Hemi-Parkinson Rats,” Brain Research 926, no. 1–2 (2002): 149–155.

[502] E. Haroon, A. H. Miller, and G. Sanacora, “Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders,” Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 42, no. 1 (2017): 193–215.

[503] S. D. Skaper, L. Facci, M. Zusso, et al., “An Inflammation-Centric View of Neurological Disease: Beyond the Neuron,” Frontiers in Cellular Neuroscience 12 (2018): 72.

[504] J. V. Andersen, K. H. Markussen, E. Jakobsen, et al., “Glutamate Metabolism and Recycling at the Excitatory Synapse in Health and Neurodegeneration,” Neuropharmacology 196 (2021): 108719.

[505] L. K. Bak, A. Schousboe, and H. S. Waagepetersen, “The Glutamate/GABA-Glutamine Cycle: Aspects of Transport, Neurotransmitter Homeostasis and Ammonia Transfer,” Journal of Neurochemistry 98, no. 3 (2006): 641–653.

[506] H. M. Abdul, M. A. Sama, J. L. Furman, et al., “Cognitive Decline in Alzheimer's Disease Is Associated With Selective Changes in Calcineurin/NFAT Signaling,” Journal of Neuroscience: The Official Journal of the Society for Neuroscience 29, no. 41 (2009): 12957–12969.

[507] T. Cassano, G. Serviddio, S. Gaetani, et al., “Glutamatergic Alterations and Mitochondrial Impairment in a Murine Model of Alzheimer Disease,” Neurobiology of Aging 33, no. 6 (2012): 1121.e1121–1121.1112.

[508] D. V. Dabir, M. B. Robinson, E. Swanson, et al., “Impaired Glutamate Transport in a Mouse Model of Tau Pathology in Astrocytes,” Journal of Neuroscience: The Official Journal of the Society for Neuroscience 26, no. 2 (2006): 644–654.

[509] J. K. Hefendehl, J. LeDue, R. W. Y. Ko, et al., “Mapping Synaptic Glutamate Transporter Dysfunction In Vivo to Regions Surrounding Aβ Plaques by iGluSnFR Two-Photon Imaging,” Nature Communications 7 (2016): 13441.

[510] M. Matos, E. Augusto, N. J. Machado, et al., “Astrocytic Adenosine A2A Receptors Control the Amyloid-β Peptide-Induced Decrease of Glutamate Uptake,” Journal of Alzheimer's Disease: JAD 31, no. 3 (2012): 555–567.

[511] A. Scimemi, J. S. Meabon, R. L. Woltjer, et al., “Amyloid-β1-42 Slows Clearance of Synaptically Released Glutamate by Mislocalizing Astrocytic GLT-1,” Journal of Neuroscience 33, no. 12 (2013): 5312–5318.

[512] T. Harkany, I. Abrahám, W. Timmerman, et al., “Beta-Amyloid Neurotoxicity Is Mediated by a Glutamate-Triggered Excitotoxic Cascade in Rat Nucleus Basalis,” European Journal of Neuroscience 12, no. 8 (2000): 2735–2745.

[513] J. Liu, L. Chang, Y. Song, et al., “The Role of NMDA Receptors in Alzheimer's Disease,” Frontiers in Neuroscience 13 (2019): 43.

[514] O. Pascual, Ben Achour, S. P. Rostaing, et al., “Microglia Activation Triggers Astrocyte-Mediated Modulation of Excitatory Neurotransmission,” Proceedings of the National Academy of Sciences of the United States of America 109, no. 4 (2012): E197–E205.

[515] R. Hamnett, J. L. Bendrick, Z. Saha, et al., “Enteric Glutamatergic Interneurons Regulate Intestinal Motility,” Neuron 113, no. 7 (2025): 1019–1035.e6.

[516] D. J. Brinkman, A. S. Ten Hove, M. J. Vervoordeldonk, et al., “Neuroimmune Interactions in the Gut and Their Significance for Intestinal Immunity,” Cells 8, no. 7 (2019).

[517] D. K. Song, H. W. Suh, S. O. Huh, et al., “Central GABAA and GABAB Receptor Modulation of Basal and Stress-Induced Plasma Interleukin-6 Levels in Mice,” Journal of Pharmacology and Experimental Therapeutics 287, no. 1 (1998): 144–149.

[518] C. S. Pinal and A. J. Tobin, “Uniqueness and Redundancy in GABA Production,” Perspectives on Developmental Neurobiology 5, no. 2–3 (1998): 109–118.

[519] T. Crowley, J. F. Cryan, E. J. Downer, et al., “Inhibiting Neuroinflammation: The Role and Therapeutic Potential of GABA in Neuro-Immune Interactions,” Brain, Behavior, and Immunity 54 (2016): 260–277.

[520] W. J. McEntee and T. H. Crook, “Glutamate: Its Role in Learning, Memory, and the Aging Brain,” Psychopharmacology 111, no. 4 (1993): 391–401.

[521] S. Z. Young and A. Bordey, “GABA's Control of Stem and Cancer Cell Proliferation in Adult Neural and Peripheral Niches,” Physiology (Bethesda, Md) 24 (2009): 171–185.

[522] H. Y. Sung, S. Yang, W. Ju, et al., “Aberrant Epigenetic Regulation of GABRP Associates With Aggressive Phenotype of Ovarian Cancer,” Experimental & Molecular Medicine 49, no. 5 (2017): e335.

[523] Z. Hujber, G. Horváth, G. Petővári, et al., “GABA, Glutamine, Glutamate Oxidation and Succinic Semialdehyde Dehydrogenase Expression in Human Gliomas,” Journal of Experimental & Clinical Cancer Research: CR 37, no. 1 (2018): 271.

[524] K. Maemura, N. Shiraishi, K. Sakagami, et al., “Proliferative Effects of Gamma-Aminobutyric Acid on the Gastric Cancer Cell Line Are Associated With Extracellular Signal-Regulated Kinase 1/2 Activation,” Journal of Gastroenterology and Hepatology 24, no. 4 (2009): 688–696.

[525] D. Zhang, X. Li, Z. Yao, et al., “GABAergic Signaling Facilitates Breast Cancer Metastasis by Promoting ERK1/2-Dependent Phosphorylation,” Cancer Letters 348, no. 1–2 (2014): 100–108.

[526] A. Blanchart, R. Fernando, M. Häring, et al., “Endogenous GABAA Receptor Activity Suppresses Glioma Growth,” Oncogene 36, no. 6 (2017): 777–786.

[527] Z. Motiwala, N. G. Aduri, H. Shaye, et al., “Structural Basis of GABA Reuptake Inhibition,” Nature 606, no. 7915 (2022): 820–826.

[528] K. Kanbara, Y. Otsuki, M. Watanabe, et al., “GABAB Receptor Regulates Proliferation in the High-Grade Chondrosarcoma Cell Line OUMS-27 via Apoptotic Pathways,” BMC Cancer 18, no. 1 (2018): 263.

[529] X. Zhang, Z. Du, J. Liu, et al., “Γ-Aminobutyric Acid Receptors Affect the Progression and Migration of Tumor Cells,” Journal of Receptor and Signal Transduction Research 34, no. 6 (2014): 431–439.

[530] K. Gumireddy, A. Li, A. V. Kossenkov, et al., “The mRNA-Edited Form of GABRA3 Suppresses GABRA3-Mediated Akt Activation and Breast Cancer Metastasis,” Nature Communications 7 (2016): 10715.

[531] S. Jiang, L. Zhu, M. Zhang, et al., “GABRP Regulates Chemokine Signalling, Macrophage Recruitment and Tumour Progression in Pancreatic Cancer Through Tuning KCNN4-Mediated Ca²⁺ Signalling in a GABA-Independent Manner,” Gut 68, no. 11 (2019): 1994–2006.

[532] M. Abdul, S. D. McCray, and N. M. Hoosein, “Expression of Gamma-Aminobutyric Acid Receptor (Subtype A) in Prostate Cancer,” Acta Oncologica (Stockholm, Sweden) 47, no. 8 (2008): 1546–1550.

[533] H. M. Schuller, “Regulatory Role of G Protein-Coupled Receptors in Pancreatic Cancer Development and Progression,” Current Medicinal Chemistry 25, no. 22 (2018): 2566–2575.

[534] Y. Liang, H. Li, Y. Gan, et al., “Shedding Light on the Role of Neurotransmitters in the Microenvironment of Pancreatic Cancer,” Frontiers in Cell and Developmental Biology 9 (2021): 688953.

[535] A. Takehara, M. Hosokawa, H. Eguchi, et al., “Gamma-Aminobutyric Acid (GABA) Stimulates Pancreatic Cancer Growth Through Overexpressing GABAA Receptor Pi Subunit,” Cancer Research 67, no. 20 (2007): 9704–9712.

[536] H. M. Schuller, “Neurotransmission and Cancer: Implications for Prevention and Therapy,” Anti-Cancer Drugs 19, no. 7 (2008): 655–671.

[537] A. Opolski, M. Mazurkiewicz, J. Wietrzyk, et al., “The Role of GABA-Ergic System in Human Mammary Gland Pathology and in Growth of Transplantable Murine Mammary Cancer,” Journal of Experimental & Clinical Cancer Research: CR 19, no. 3 (2000): 383–390.

[538] J. Neman, J. Termini, S. Wilczynski, et al., “Human Breast Cancer Metastases to the Brain Display GABAergic Properties in the Neural Niche,” Proceedings of the National Academy of Sciences of the United States of America 111, no. 3 (2014): 984–989.

[539] Y. Qiu, G. Cai, B. Zhou, et al., “A Distinct Metabolic Signature of Human Colorectal Cancer With Prognostic Potential,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 20, no. 8 (2014): 2136–2146.

[540] J. An, H. Seok, and E. Ha, “GABA-Producing Lactobacillus plantarum Inhibits Metastatic Properties and Induces Apoptosis of 5-FU-Resistant Colorectal Cancer Cells via GABAB Receptor Signaling,” Journal of Microbiology (Seoul, Korea) 59, no. 2 (2021): 202–216.

[541] L. Song, A. Du, Y. Xiong, et al., “γ-Aminobutyric Acid Inhibits the Proliferation and Increases Oxaliplatin Sensitivity in Human Colon Cancer Cells,” Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine 37, no. 11 (2016): 14885–14894.

[542] D. Huang, Y. Wang, J. W. Thompson, et al., “Cancer-Cell-Derived GABA Promotes β-Catenin-Mediated Tumour Growth and Immunosuppression,” Nature Cell Biology 24, no. 2 (2022): 230–241.

[543] G. M. Sizemore, S. T. Sizemore, D. D. Seachrist, et al., “GABA(A) Receptor Pi (GABRP) Stimulates Basal-Like Breast Cancer Cell Migration Through Activation of Extracellular-Regulated Kinase 1/2 (ERK1/2),” Journal of Biological Chemistry 289, no. 35 (2014): 24102–24113.

[544] S. Xia, C. He, Y. Zhu, et al., “GABABR-Induced EGFR Transactivation Promotes Migration of Human Prostate Cancer Cells,” Molecular Pharmacology 92, no. 3 (2017): 265–277.

[545] A. Ortega, “A New Role for GABA: Inhibition of Tumor Cell Migration,” Trends in Pharmacological Sciences 24, no. 4 (2003): 151–154.

[546] J. Joseph, B. Niggemann, K. S. Zaenker, et al., “The Neurotransmitter Gamma-Aminobutyric Acid Is an Inhibitory Regulator for the Migration of SW 480 Colon Carcinoma Cells,” Cancer Research 62, no. 22 (2002): 6467–6469.

[547] H. Bao, Z. Peng, X. Cheng, et al., “GABA Induced by Sleep Deprivation Promotes the Proliferation and Migration of Colon Tumors Through miR-223-3p Endogenous Pathway and Exosome Pathway,” Journal of Experimental & Clinical Cancer Research: CR 42, no. 1 (2023): 344.

[548] L. Li, Y. Kang, R. Cheng, et al., “The De Novo Synthesis of GABA and Its Gene Regulatory Function Control Hepatocellular Carcinoma Metastasis,” Developmental Cell 60, no. 7 (2025): 1053–1069.e6.

[549] K. Liu, Y. Zhang, G. Du, et al., “5-HT Orchestrates Histone Serotonylation and Citrullination to Drive Neutrophil Extracellular Traps and Liver Metastasis,” Journal of Clinical Investigation 135, no. 8 (2025): e183544.

[550] Y. Dong, G. Wang, D. Nie, et al., “Tumor-Derived GABA Promotes Lung Cancer Progression by Influencing TAMs Polarization and Neovascularization,” International Immunopharmacology 126 (2024): 111217.

[551] S. Alam, D. L. Laughton, A. Walding, et al., “Human Peripheral Blood Mononuclear Cells Express GABAA Receptor Subunits,” Molecular Immunology 43, no. 9 (2006): 1432–1442.

[552] L. Dionisio, M. José De Rosa, C. Bouzat, et al., “An Intrinsic GABAergic System in Human Lymphocytes,” Neuropharmacology 60, no. 2–3 (2011): 513–519.

[553] S. K. Mendu, A. Bhandage, Z. Jin, et al., “Different Subtypes of GABAA Receptors Are Expressed in Human, Mouse and Rat T Lymphocytes,” PLoS ONE 7, no. 8 (2012): e42959.

[554] J. Tian, Y. Lu, H. Zhang, et al., “Gamma-Aminobutyric Acid Inhibits T Cell Autoimmunity and the Development of Inflammatory Responses in a Mouse Type 1 Diabetes Model,” Journal of Immunology (Baltimore, Md) 173, no. 8 (2004): 5298–5304.

[555] L. Januzi, J. W. Poirier, M. J. E. Maksoud, et al., “Autocrine GABA Signaling Distinctively Regulates Phenotypic Activation of Mouse Pulmonary Macrophages,” Cellular Immunology 332 (2018): 7–23.

[556] J. M. Fuks, R. B. G. Arrighi, J. M. Weidner, et al., “GABAergic Signaling Is Linked to a Hypermigratory Phenotype in Dendritic Cells Infected by Toxoplasma gondii,” PLoS Pathogens 8, no. 12 (2012): e1003051.

[557] A. K. Bhandage, Z. Jin, S. V. Korol, et al., “GABA Regulates Release of Inflammatory Cytokines From Peripheral Blood Mononuclear Cells and CD4+ T Cells and Is Immunosuppressive in Type 1 Diabetes,” EBioMedicine 30 (2018): 283–294.

[558] E. L. Sparrow, S. James, K. Hussain, et al., “Activation of GABA(A) Receptors Inhibits T Cell Proliferation,” PLoS ONE 16, no. 5 (2021): e0251632.

[559] W. Cen, G. Fu, X. Wang, et al., “GABRP Mediates GABAA Receptor to Shape Tumor Immunosuppressive Microenvironment and Promote Tumor Immune Escape and Corresponding Targeted Therapy,” Cancer Medicine 14, no. 11 (2025): e70946.

[560] A. Barragan, J. M. Weidner, Z. Jin, et al., “GABAergic Signalling in the Immune System,” Acta Physiologica (Oxford, England) 213, no. 4 (2015): 819–827.

[561] R. Bhat, R. Axtell, A. Mitra, et al., “Inhibitory Role for GABA in Autoimmune Inflammation,” Proceedings of the National Academy of Sciences of the United States of America 107, no. 6 (2010): 2580–2585.

[562] X. Zhou, Z. Chen, Y. Yu, et al., “Increases in 4-Acetaminobutyric Acid Generated by Phosphomevalonate Kinase Suppress CD8+ T Cell Activation and Allow Tumor Immune Escape,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 11, no. 43 (2024): e2403629.

[563] D. L. Kaufman. A Neurotransmitter Limits Antitumour Responses, Vol. 599 (Nature Portfolio, 2021).

[564] B. Zhang, A. Vogelzang, M. Miyajima, et al., “B Cell-Derived GABA Elicits IL-10+ Macrophages to Limit Anti-Tumour Immunity,” Nature 599, no. 7885 (2021): 471–476.

[565] D. A. Pomeranz Krummel, T. H. Nasti, M. Kaluzova, et al., “Melanoma Cell Intrinsic GABAA Receptor Enhancement Potentiates Radiation and Immune Checkpoint Inhibitor Response by Promoting Direct and T Cell-Mediated Antitumor Activity,” International Journal of Radiation Oncology, Biology, Physics 109, no. 4 (2021): 1040–1053.

[566] Y. Wang, Q. J. Zhang, J. Liu, et al., “Changes in Firing Rate and Pattern of GABAergic Neurons in Subregions of the Substantia Nigra Pars Reticulata in Rat Models of Parkinson's Disease,” Brain Research 1324 (2010): 54–63.

[567] Y. Song, T. Gong, M. G. Saleh, et al., “Upper Brainstem GABA Levels in Parkinson's Disease,” Magma (New York, NY) 34, no. 5 (2021): 689–696.

[568] R. Melani and N. X. Tritsch, “Inhibitory Co-Transmission From Midbrain Dopamine Neurons Relies on Presynaptic GABA Uptake,” Cell Reports 39, no. 3 (2022): 110716.

[569] J. C. Lemos, D. M. Friend, A. R. Kaplan, et al., “Enhanced GABA Transmission Drives Bradykinesia Following Loss of Dopamine D2 Receptor Signaling,” Neuron 90, no. 4 (2016): 824–838.

[570] J. W. Błaszczyk, “Parkinson's Disease and Neurodegeneration: GABA-Collapse Hypothesis,” Frontiers in Neuroscience 10 (2016): 269.

[571] S. Nath, J. Goodwin, Y. Engelborghs, et al., “Raised Calcium Promotes α-Synuclein Aggregate Formation,” Molecular and Cellular Neurosciences 46, no. 2 (2011): 516–526.

[572] N. H. Ali, N. A. Alhamdan, H. M. Al-Kuraishy, et al., “Irisin/PGC-1α/FNDC5 Pathway in Parkinson's Disease: Truth Under the Throes,” Naunyn-Schmiedeberg's Archives of Pharmacology 397, no. 4 (2024): 1985–1995.

[573] S. Luchetti, I. Huitinga, and D. F. Swaab, “Neurosteroid and GABAA Receptor Alterations in Alzheimer's Disease, Parkinson's Disease and Multiple Sclerosis,” Neuroscience 191 (2011): 6–21.

[574] A. C. Lanoue, A. Dumitriu, R. H. Myers, et al., “Decreased Glutamic Acid Decarboxylase mRNA Expression in Prefrontal Cortex in Parkinson's Disease,” Experimental Neurology 226, no. 1 (2010): 207–217.

[575] W. Zhang, B. Xiong, L. Zhang, et al., “The Role of the GABAergic System in Diseases of the Central Nervous System,” Neuroscience 470 (2021): 88–99.

[576] R. Hajj, A. Milet, D. Toulorge, et al., “Combination of Acamprosate and Baclofen as a Promising Therapeutic Approach for Parkinson's Disease,” Scientific Reports 5 (2015): 16084.

[577] A. Daniele, F. Panza, A. Greco, et al., “Can a Positive Allosteric Modulation of GABAergic Receptors Improve Motor Symptoms in Patients with Parkinson's Disease? The Potential Role of Zolpidem in the Treatment of Parkinson's Disease,” Parkinson's Disease 2016 (2016): 2531812.

[578] B. Alharbi, H. M. Al-Kuraishy, A. I. Al-Gareeb, et al., “Role of GABA Pathway in Motor and Non-Motor Symptoms in Parkinson's Disease: A Bidirectional Circuit,” European Journal of Medical Research 29, no. 1 (2024): 205.

[579] B. Calvo-Flores Guzmán, C. Vinnakota, K. Govindpani, et al., “The GABAergic System as a Therapeutic Target for Alzheimer's Disease,” Journal of Neurochemistry 146, no. 6 (2018): 649–669.

[580] K. L. Lanctôt, N. Herrmann, P. Mazzotta, et al., “GABAergic Function in Alzheimer's Disease: Evidence for Dysfunction and Potential as a Therapeutic Target for the Treatment of Behavioural and Psychological Symptoms of Dementia,” Canadian Journal of Psychiatry Revue Canadienne de Psychiatrie 49, no. 7 (2004): 439–453.

[581] Y. Li, H. Sun, Z. Chen, et al., “Implications of GABAergic Neurotransmission in Alzheimer's Disease,” Frontiers in Aging Neuroscience 8 (2016): 31.

[582] M. A. Busche, X. Chen, H. A. Henning, et al., “Critical Role of Soluble Amyloid-β for Early Hippocampal Hyperactivity in a Mouse Model of Alzheimer's Disease,” Proceedings of the National Academy of Sciences of the United States of America 109, no. 22 (2012): 8740–8745.

[583] M. A. Busche, G. Eichhoff, H. Adelsberger, et al., “Clusters of Hyperactive Neurons Near Amyloid Plaques in a Mouse Model of Alzheimer's Disease,” Science (New York, NY) 321, no. 5896 (2008): 1686–1689.

[584] H. A. Born, “Seizures in Alzheimer's Disease,” Neuroscience 286 (2015): 251–263.

[585] S. Jo, O. Yarishkin, Y. J. Hwang, et al., “GABA From Reactive Astrocytes Impairs Memory in Mouse Models of Alzheimer's Disease,” Nature Medicine 20, no. 8 (2014): 886–896.

[586] Z. Wu, Z. Guo, M. Gearing, et al., “Tonic Inhibition in Dentate Gyrus Impairs Long-Term Potentiation and Memory in an Alzheimer's [Corrected] Disease Model,” Nature Communications 5 (2014): 4159.

[587] G. A. Czapski and J. B. Strosznajder, “Glutamate and GABA in Microglia-Neuron Cross-Talk in Alzheimer's Disease,” International Journal of Molecular Sciences 22, no. 21 (2021): 11677.

[588] K. Govindpani, B. Calvo-Flores Guzmán, C. Vinnakota, et al., “Towards a Better Understanding of GABAergic Remodeling in Alzheimer's Disease,” International Journal of Molecular Sciences 18, no. 8 (2017): 1813.

[589] A. Kwakowsky, B. Calvo-Flores Guzmán, M. Pandya, et al., “GABAA Receptor Subunit Expression Changes in the Human Alzheimer's Disease Hippocampus, Subiculum, Entorhinal Cortex and Superior Temporal Gyrus,” Journal of Neurochemistry 145, no. 5 (2018): 374–392.

[590] T. E. Fuhrer, T. H. Palpagama, H. J. Waldvogel, et al., “Impaired Expression of GABA Transporters in the Human Alzheimer's Disease Hippocampus, Subiculum, Entorhinal Cortex and Superior Temporal Gyrus,” Neuroscience 351 (2017): 108–118.

[591] F. Sherif, C. G. Gottfries, I. Alafuzoff, et al., “Brain Gamma-Aminobutyrate Aminotransferase (GABA-T) and Monoamine Oxidase (MAO) in Patients With Alzheimer's Disease,” Journal of Neural Transmission Parkinson's Disease and Dementia Section 4, no. 3 (1992): 227–240.

[592] J. V. Andersen, S. K. Christensen, B. I. Aldana, et al., “Alterations in Cerebral Cortical Glucose and Glutamine Metabolism Precedes Amyloid Plaques in the APPswe/PSEN1dE9 Mouse Model of Alzheimer's Disease,” Neurochemical Research 42, no. 6 (2017): 1589–1598.

[593] S. Li, S. Hong, N. E. Shepardson, et al., “Soluble Oligomers of Amyloid Beta Protein Facilitate Hippocampal Long-Term Depression by Disrupting Neuronal Glutamate Uptake,” Neuron 62, no. 6 (2009): 788–801.

[594] E. Sanchez-Mejias, C. Nuñez-Diaz, R. Sanchez-Varo, et al., “Distinct Disease-Sensitive GABAergic Neurons in the Perirhinal Cortex of Alzheimer's Mice and Patients,” Brain Pathology (Zurich, Switzerland) 30, no. 2 (2020): 345–363.

[595] T. Vazin, K. A. Ball, H. Lu, et al., “Efficient Derivation of Cortical Glutamatergic Neurons From Human Pluripotent Stem Cells: A Model System to Study Neurotoxicity in Alzheimer's Disease,” Neurobiology of Disease 62 (2014): 62–72.

[596] K. Govindpani, C. Turner, H. J. Waldvogel, et al., “Impaired Expression of GABA Signaling Components in the Alzheimer's Disease Middle Temporal Gyrus,” International Journal of Molecular Sciences 21, no. 22 (2020): 8704.

[597] J. Zumkehr, C. J. Rodriguez-Ortiz, D. Cheng, et al., “Ceftriaxone Ameliorates Tau Pathology and Cognitive Decline via Restoration of Glial Glutamate Transporter in a Mouse Model of Alzheimer's Disease,” Neurobiology of Aging 36, no. 7 (2015): 2260–2271.

[598] S. A. Kuhn, F. K. H. van Landeghem, R. Zacharias, et al., “Microglia Express GABA(B) Receptors to Modulate Interleukin Release,” Molecular and Cellular Neurosciences 25, no. 2 (2004): 312–322.

[599] M. Lee, C. Schwab, and P. L. McGeer, “Astrocytes Are GABAergic Cells That Modulate Microglial Activity,” Glia 59, no. 1 (2011): 152–165.

[600] L. Lang, B. Xu, J. Yuan, et al., “GABA-Mediated Activated Microglia Induce Neuroinflammation in the Hippocampus of Mice Following Cold Exposure Through the NLRP3 Inflammasome and NF-κB Signaling Pathways,” International Immunopharmacology 89, no. pt. B (2020): 106908.

[601] H. F. Iaccarino, A. C. Singer, A. J. Martorell, et al., “Gamma Frequency Entrainment Attenuates Amyloid Load and Modifies Microglia,” Nature 540, no. 7632 (2016): 230–235.

[602] K. Kaczyńska, D. Zając, P. Wojciechowski, et al., “Neuropeptides and Breathing in Health and Disease,” Pulmonary Pharmacology & Therapeutics 48 (2018): 217–224.

[603] C. Palma, “Tachykinins and Their Receptors in Human Malignancies,” Current Drug Targets 7, no. 8 (2006): 1043–1052.

[604] T. Hökfelt, B. Pernow, and J. Wahren, “Substance P: A Pioneer Amongst Neuropeptides,” Journal of Internal Medicine 249, no. 1 (2001): 27–40.

[605] M. Munoz, R. Covenas, F. Esteban, et al., “The Substance P/NK-1 Receptor System: NK-1 Receptor Antagonists as Anti-Cancer Drugs,” Journal of Biosciences 40, no. 2 (2015): 441–463.

[606] X. Chen, G. Ru, Y. Ma, et al., “High Expression of Substance P and Its Receptor Neurokinin-1 Receptor in Colorectal Cancer Is Associated With Tumor Progression and Prognosis,” OncoTargets and Therapy 9 (2016): 3595–3602.

[607] L. Quartara and C. A. Maggi, “The Tachykinin NK1 Receptor. Part II: Distribution and Pathophysiological Roles,” Neuropeptides 32, no. 1 (1998): 1–49.

[608] M. Muñoz, M. Rosso, M. J. Robles-Frias, et al., “The NK-1 Receptor Is Expressed in Human Melanoma and Is Involved in the Antitumor Action of the NK-1 Receptor Antagonist Aprepitant on Melanoma Cell Lines,” Laboratory Investigation; A Journal of Technical Methods and Pathology 90, no. 8 (2010): 1259–1269.

[609] F. Esteban, M. A. Gonzalez-Moles, D. Castro, et al., “Expression of Substance P and Neurokinin-1-Receptor in Laryngeal Cancer: Linking Chronic Inflammation to Cancer Promotion and Progression,” Histopathology 54, no. 2 (2009): 258–260.

[610] I. M. Hennig, J. A. Laissue, U. Horisberger, et al., “Substance-P Receptors in Human Primary Neoplasms: Tumoral and Vascular Localization,” International Journal of Cancer 61, no. 6 (1995): 786–792.

[611] S. Schulz, R. Stumm, C. Röcken, et al., “Immunolocalization of Full-Length NK1 Tachykinin Receptors in Human Tumors,” Journal of Histochemistry and Cytochemistry: Official Journal of the Histochemistry Society 54, no. 9 (2006): 1015–1020.

[612] P. Dietrich, L. Wormser, V. Fritz, et al., “Molecular Crosstalk Between Y5 Receptor and Neuropeptide Y Drives Liver Cancer,” Journal of Clinical Investigation 130, no. 5 (2020): 2509–2526.

[613] J. C. Reubi, M. Gugger, B. Waser, et al., “Y(1)-Mediated Effect of Neuropeptide Y in Cancer: Breast Carcinomas as Targets,” Cancer Research 61, no. 11 (2001): 4636–4641.

[614] X. Li, G. Ma, Q. Ma, et al., “Neurotransmitter Substance P Mediates Pancreatic Cancer Perineural Invasion via NK-1R in Cancer Cells,” Molecular Cancer Research: MCR 11, no. 3 (2013): 294–302.

[615] H. R. Eistetter, A. Mills, R. Brewster, et al., “Functional Characterization of Neurokinin-1 Receptors on Human U373MG Astrocytoma Cells,” Glia 6, no. 2 (1992): 89–95.

[616] M. Muñoz, M. Rosso, and R. Coveñas, “The NK-1 Receptor: A New Target in Cancer Therapy,” Current Drug Targets 12, no. 6 (2011): 909–921.

[617] M. Muñoz and M. Rosso, “The NK-1 Receptor Antagonist Aprepitant as a Broad Spectrum Antitumor Drug,” Investigational New Drugs 28, no. 2 (2010): 187–193.

[618] M. Muñoz and R. Coveñas, “Neurokinin-1 Receptor Antagonists as Antitumor Drugs in Gastrointestinal Cancer: A New Approach,” Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association 22, no. 4 (2016): 260–268.

[619] M. Muñoz, M. Rosso, and R. Coveñas, “The NK-1 Receptor Antagonist L-732,138 Induces Apoptosis in Human Gastrointestinal Cancer Cell Lines,” Pharmacological Reports: PR 69, no. 4 (2017): 696–701.

[620] S. M. Gysler and R. Drapkin, “Tumor Innervation: Peripheral Nerves Take Control of the Tumor Microenvironment,” Journal of Clinical Investigation 131, no. 11 (2021): e147276.

[621] M. Ruscica, E. Dozio, M. Motta, et al., “Relevance of the Neuropeptide Y System in the Biology of Cancer Progression,” Current Topics in Medicinal Chemistry 7, no. 17 (2007): 1682–1691.

[622] M. Körner and J. C. Reubi, “NPY Receptors in Human Cancer: A Review of Current Knowledge,” Peptides 28, no. 2 (2007): 419–425.

[623] O. Nagakawa, M. Ogasawara, J. Murata, et al., “Effect of Prostatic Neuropeptides on Migration of Prostate Cancer Cell Lines,” International Journal of Urology: Official Journal of the Japanese Urological Association 8, no. 2 (2001): 65–70.

[624] X. Ge, Y. Cao, X. Zhu, et al., “Self-Assembly of Organelle-Localized Neuropeptides Triggers Intrinsic Apoptosis Against Breast Cancer,” Advanced Healthcare Materials 12, no. 25 (2023): e2300265.

[625] P. J. Medeiros, B. K. Al-Khazraji, N. M. Novielli, et al., “Neuropeptide Y Stimulates Proliferation and Migration in the 4T1 Breast Cancer Cell Line,” International Journal of Cancer 131, no. 2 (2012): 276–286.

[626] Y. Ding, M. Lee, Y. Gao, et al., “Neuropeptide Y Nerve Paracrine Regulation of Prostate Cancer Oncogenesis and Therapy Resistance,” Prostate 81, no. 1 (2021): 58–71.

[627] M. Ruscica, E. Dozio, M. Motta, et al., “Modulatory Actions of Neuropeptide Y on Prostate Cancer Growth: Role of MAP Kinase/ERK 1/2 Activation,” Advances in Experimental Medicine and Biology 604 (2007): 96–100.

[628] M. Czarnecka, E. Trinh, C. Lu, et al., “Neuropeptide Y Receptor Y5 as an Inducible Pro-Survival Factor in Neuroblastoma: Implications for Tumor Chemoresistance,” Oncogene 34, no. 24 (2015): 3131–3143.

[629] M. Ziche, L. Morbidelli, M. Pacini, et al., “Substance P Stimulates Neovascularization In Vivo and Proliferation of Cultured Endothelial Cells,” Microvascular Research 40, no. 2 (1990): 264–278.

[630] L. Liu, R. Dana, and J. Yin, “Sensory Neurons Directly Promote Angiogenesis in Response to Inflammation via Substance P Signaling,” FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 34, no. 5 (2020): 6229–6243.

[631] V. Padmanaban, I. Keller, E. S. Seltzer, et al., “Neuronal Substance P Drives Metastasis Through an Extracellular RNA-TLR7 Axis,” Nature 633, no. 8028 (2024): 207–215.

[632] J. Waldmann, V. Fendrich, M. Reichert, et al., “Expression of Neuropeptide Y and Its Receptors Y1 and Y2 in Pancreatic Intraepithelial Neoplasia and Invasive Pancreatic Cancer in a Transgenic Mouse Model and Human Samples of Pancreatic Cancer,” Journal of Surgical Research 223 (2018): 230–236.

[633] C. Feistritzer, J. Clausen, D. H. Sturn, et al., “Natural Killer Cell Functions Mediated by the Neuropeptide Substance P,” Regulatory Peptides 116, no. 1–3 (2003): 119–126.

[634] I. Marriott and K. L. Bost, “Expression of Authentic Substance P Receptors in Murine and Human Dendritic Cells,” Journal of Neuroimmunology 114, no. 1–2 (2001): 131–141.

[635] D. G. Payan, D. R. Brewster, and E. J. Goetzl, “Specific Stimulation of Human T Lymphocytes by Substance P,” Journal of Immunology (Baltimore, Md) 131, no. 4 (1983): 1613–1615.

[636] P. R. Germonpre, G. R. Bullock, B. N. Lambrecht, et al., “Presence of Substance P and Neurokinin 1 Receptors in Human Sputum Macrophages and U-937 Cells,” European Respiratory Journal 14, no. 4 (1999): 776–782.

[637] H. P. M. van der Kleij, D. Ma, F. A. M. Redegeld, et al., “Functional Expression of Neurokinin 1 Receptors on Mast Cells Induced by IL-4 and Stem Cell Factor,” Journal of Immunology (Baltimore, Md) 171, no. 4 (2003): 2074–2079.

[638] M. M. Chang and S. E. Leeman, “Isolation of a Sialogogic Peptide From Bovine Hypothalamic Tissue and Its Characterization as Substance P,” Journal of Biological Chemistry 245, no. 18 (1970): 4784–4790.

[639] H. S. Kang, K. A. Trzaska, K. Corcoran, et al., “Neurokinin Receptors: Relevance to the Emerging Immune System,” Archivum Immunologiae et Therapiae Experimentalis 52, no. 5 (2004): 338–347.

[640] J. E. Krause, Y. Takeda, and A. D. Hershey, “Structure, Functions, and Mechanisms of Substance P Receptor Action,” Journal of Investigative Dermatology 98, no. 6 suppl. (1992): 2S–7S.

[641] J. P. Lai, S. D. Douglas, and W. Z. Ho, “Human Lymphocytes Express Substance P and Its Receptor,” Journal of Neuroimmunology 86, no. 1 (1998): 80–86.

[642] M. Levite, “Neurotransmitters Activate T-Cells and Elicit Crucial Functions via Neurotransmitter Receptors,” Current Opinion in Pharmacology 8, no. 4 (2008): 460–471.

[643] J. Y. Liu, J. H. Hu, Q. G. Zhu, et al., “Substance P Receptor Expression in Human Skin Keratinocytes and Fibroblasts,” British Journal of Dermatology 155, no. 4 (2006): 657–662.

[644] P. W. Mantyh, “Substance P and the Inflammatory and Immune Response,” Annals of the New York Academy of Sciences 632 (1991): 263–271.

[645] P. Cunin, A. Caillon, M. Corvaisier, et al., “The Tachykinins Substance P and Hemokinin-1 Favor the Generation of Human Memory Th17 Cells by Inducing IL-1β, IL-23, and TNF-Like 1A Expression by Monocytes,” Journal of Immunology (Baltimore, Md) 186, no. 7 (2011): 4175–4182.

[646] A. Mashaghi, A. Marmalidou, M. Tehrani, et al., “Neuropeptide Substance P and the Immune Response,” Cellular and Molecular Life Sciences: CMLS 73, no. 22 (2016): 4249–4264.

[647] Y. Cheng, X. Tang, Y. Li, et al., “Depression-Induced Neuropeptide Y Secretion Promotes Prostate Cancer Growth by Recruiting Myeloid Cells,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 25, no. 8 (2019): 2621–2632.

[648] E. Catalani, C. De Palma, C. Perrotta, et al., “Current Evidence for a Role of Neuropeptides in the Regulation of Autophagy,” BioMed Research International 2017 (2017): 5856071.

[649] S. Wang, L. Chen, Y. Xue, et al., “Substance P Prevents 1-Methyl-4-Phenylpyridinium-Induced Cytotoxicity Through Inhibition of Apoptosis via Neurokinin-1 Receptors in MES23.5 Cells,” Molecular Medicine Reports 12, no. 6 (2015): 8085–8092.

[650] L. Shi, X. Du, H. Jiang, et al., “Ghrelin and Neurodegenerative Disorders - A Review,” Molecular Neurobiology 54, no. 2 (2017): 1144–1155.

[651] J. A. Bayliss, M. Lemus, V. V. Santos, et al., “Acylated but not Des-Acyl Ghrelin is Neuroprotective in an MPTP Mouse Model of Parkinson's Disease,” Journal of Neurochemistry 137, no. 3 (2016): 460–471.

[652] C. Li, X. Wu, S. Liu, et al., “Roles of Neuropeptide Y in Neurodegenerative and Neuroimmune Diseases,” Frontiers in Neuroscience 13 (2019): 869.

[653] M. Lazarova, A. Popatanasov, R. Klissurov, et al., “Preventive Effect of Two New Neurotensin Analogues on Parkinson's Disease Rat Model,” Journal of Molecular Neuroscience: MN 66, no. 4 (2018): 552–560.

[654] G. Maasz, Z. Zrinyi, D. Reglodi, et al., “Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Has a Neuroprotective Function in Dopamine-Based Neurodegeneration in Rat and Snail Parkinsonian Models,” Disease Models & Mechanisms 10, no. 2 (2017): 127–139.

[655] A. Mauborgne, F. Javoy-Agid, J. C. Legrand, et al., “Decrease of Substance P-Like Immunoreactivity in the Substantia Nigra and Pallidum of Parkinsonian Brains,” Brain Research 268, no. 1 (1983): 167–170.

[656] E. Thornton and R. Vink, “Treatment With a Substance P Receptor Antagonist Is Neuroprotective in the Intrastriatal 6-Hydroxydopamine Model of Early Parkinson's Disease,” PLoS ONE 7, no. 4 (2012): e34138.

[657] Y. Zheng, L. Zhang, J. Xie, et al., “The Emerging Role of Neuropeptides in Parkinson's Disease,” Frontiers in Aging Neuroscience 13 (2021): 646726.

[658] J. M. T. Chu, L. W. Chen, Y. S. Chan, et al., “Neuroprotective Effects of Neurokinin Receptor One in Dopaminergic Neurons Are Mediated Through Akt/PKB Cell Signaling Pathway,” Neuropharmacology 61, no. 8 (2011): 1389–1398.

[659] G. Amadoro, M. Pieri, M. T. Ciotti, et al., “Substance P Provides Neuroprotection in Cerebellar Granule Cells Through Akt and MAPK/Erk Activation: Evidence for the Involvement of the Delayed Rectifier Potassium Current,” Neuropharmacology 52, no. 6 (2007): 1366–1377.

[660] E. Thornton, T. T. B. Tran, and R. Vink, “A Substance P Mediated Pathway Contributes to 6-Hydroxydopamine Induced Cell Death,” Neuroscience Letters 481, no. 1 (2010): 64–67.

[661] J. B. Schröder, T. Marian, I. Claus, et al., “Substance P Saliva Reduction Predicts Pharyngeal Dysphagia in Parkinson's Disease,” Frontiers in Neurology 10 (2019): 386.

[662] T. Behl, P. Madaan, A. Sehgal, et al., “Demystifying the Neuroprotective Role of Neuropeptides in Parkinson's Disease: A Newfangled and Eloquent Therapeutic Perspective,” International Journal of Molecular Sciences 23, no. 9 (2022): 4565.

[663] M. Decressac, S. Pain, P. Chabeauti, et al., “Neuroprotection by Neuropeptide Y in Cell and Animal Models of Parkinson's Disease,” Neurobiology of Aging 33, no. 9 (2012): 2125–2137.

[664] S. Pain, J. Vergote, Z. Gulhan, et al., “Inflammatory Process in Parkinson Disease: Neuroprotection by Neuropeptide Y,” Fundamental & Clinical Pharmacology 33, no. 5 (2019): 544–548.

[665] R. Ferreira, S. Xapelli, T. Santos, et al., “Neuropeptide Y Modulation of Interleukin-1{Beta} (IL-1{Beta})-Induced Nitric Oxide Production in Microglia,” Journal of Biological Chemistry 285, no. 53 (2010): 41921–41934.

[666] D. Y. Lee, S. H. Hong, B. Kim, et al., “Neuropeptide Y Mitigates ER Stress-Induced Neuronal Cell Death by Activating the PI3K-XBP1 Pathway,” European Journal of Cell Biology 97, no. 5 (2018): 339–348.

[667] E. Thornton, M. M. Hassall, F. Corrigan, et al., “The NK1 Receptor Antagonist N-Acetyl-L-Tryptophan Reduces Dyskinesia in a Hemi-Parkinsonian Rodent Model,” Parkinsonism & Related Disorders 20, no. 5 (2014): 508–513.

[668] C. Cannizzaro, B. C. Tel, S. Rose, et al., “Increased Neuropeptide Y mRNA Expression in Striatum in Parkinson's Disease,” Brain Research Molecular Brain Research 110, no. 2 (2003): 169–176.

[669] E. Martignoni, F. Blandini, F. Petraglia, et al., “Cerebrospinal Fluid Norepinephrine, 3-Methoxy-4-Hydroxyphenylglycol and Neuropeptide Y Levels in Parkinson's Disease, Multiple System Atrophy and Dementia of the Alzheimer Type,” Journal of Neural Transmission Parkinson's Disease and Dementia Section 4, no. 3 (1992): 191–205.

[670] J. A. Driver, G. Logroscino, J. M. Gaziano, et al., “Incidence and Remaining Lifetime Risk of Parkinson Disease in Advanced Age,” Neurology 72, no. 5 (2009): 432–438.

[671] K. Schebesch, A. Herbst, S. Bele, et al., “Calcitonin-Gene Related Peptide and Cerebral Vasospasm,” Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia 20, no. 4 (2013): 584–586.

[672] L. A. Mohamed, H. Zhu, Y. M. Mousa, et al., “Amylin Enhances Amyloid-β Peptide Brain to Blood Efflux Across the Blood-Brain Barrier,” Journal of Alzheimer's Disease: JAD 56, no. 3 (2017): 1087–1099.

[673] L. Zhai, T. Sakurai, A. Kamiyoshi, et al., “Endogenous Calcitonin Gene-Related Peptide Suppresses Ischemic Brain Injuries and Progression of Cognitive Decline,” Journal of Hypertension 36, no. 4 (2018): 876–891.

[674] Y. Singh, G. Gupta, B. Shrivastava, et al., “Calcitonin Gene-Related Peptide (CGRP): A Novel Target for Alzheimer's Disease,” CNS Neuroscience & Therapeutics 23, no. 6 (2017): 457–461.

[675] G. Papiri, S. Luzzi, M. Marcucci, et al., “Vasoactive Neuropeptides and Alzheimer's Sisease: A Systematic Review Focusing on Calcitonin Gene-Related Peptide,” Journal of Integrative Neuroscience 20, no. 4 (2021): 1059–1065.

[676] M. D. Harzenetter, A. R. Novotny, P. Gais, et al., “Negative Regulation of TLR Responses by the Neuropeptide CGRP Is Mediated by the Transcriptional Repressor ICER,” Journal of Immunology (Baltimore, Md) 179, no. 1 (2007): 607–615.

[677] A. N'Diaye, A. Gannesen, V. Borrel, et al., “Substance P and Calcitonin Gene-Related Peptide: Key Regulators of Cutaneous Microbiota Homeostasis,” Frontiers in Endocrinology 8 (2017): 15.

[678] J. Aresti Sanz and S. El Aidy, “Microbiota and gut neuropeptides: A dual action of antimicrobial activity and neuroimmune response,” Psychopharmacology 236, no. 5 (2019): 1597–1609.

[679] Z. Fang, Y. Fu, F. Yi, et al., “Neural Control of the Pathophysiology of Allergic Airway Disease and Its Clinical Implications: A Focus on Allergic Rhinitis and Asthma,” Journal of Allergy and Clinical Immunology 156, no. 2 (2025): 259–269.

[680] M. G. Drake, K. M. Lebold, R. QR, et al., “Eosinophil and Airway Nerve Interactions in Asthma,” Journal of Leukocyte Biology 104, no. 1 (2018): 61–67.

[681] H. W. Chu, M. Kraft, J. E. Krause, et al., “Substance P and Its Receptor Neurokinin 1 Expression in Asthmatic Airways,” Journal of Allergy and Clinical Immunology 106, no. 4 (2000): 713–722.

[682] N. Wang, J. Wang, Y. Zhang, et al., “Substance P-Induced Lung Inflammation in Mice Is Mast Cell Dependent,” Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 52, no. 1 (2022): 46–58.

[683] T. Crosson, J. Wang, B. Doyle, et al., “FcεR1-Expressing Nociceptors Trigger Allergic Airway Inflammation,” Journal of Allergy and Clinical Immunology 147, no. 6 (2021): 2330–2342.

[684] K. R. Atanasova and L. R. Reznikov, “Neuropeptides in Asthma, Chronic Obstructive Pulmonary Disease and Cystic Fibrosis,” Respiratory Research 19, no. 1 (2018): 149.

[685] J. Springer, P. Geppetti, A. Fischer, et al., “Calcitonin Gene-Related Peptide as Inflammatory Mediator,” Pulmonary Pharmacology & Therapeutics 16, no. 3 (2003): 121–130.

[686] J. Springer, S. Amadesi, M. Trevisani, et al., “Effects of Alpha Calcitonin Gene-Related Peptide in Human Bronchial Smooth Muscle and Pulmonary Artery,” Regulatory Peptides 118, no. 3 (2004): 127–134.

[687] A. B. Kay, F. R. Ali, L. G. Heaney, et al., “Airway Expression of Calcitonin Gene-Related Peptide in T-Cell Peptide-Induced Late Asthmatic Reactions in Atopics,” Allergy 62, no. 5 (2007): 495–503.

[688] F. Vafaee, S. Shirzad, F. Shamsi, et al., “Neuroscience and Treatment of Asthma, New Therapeutic Strategies and Future Aspects,” Life Sciences 292 (2022): 120175.

[689] D. A. Groneberg, J. Springer, and A. Fischer, “Vasoactive Intestinal Polypeptide as Mediator of Asthma,” Pulmonary Pharmacology & Therapeutics 14, no. 5 (2001): 391–401.

[690] L. O. Cardell, R. Uddman, and L. Edvinsson, “Low Plasma Concentrations of VIP and Elevated Levels of Other Neuropeptides During Exacerbations of Asthma,” European Respiratory Journal 7, no. 12 (1994): 2169–2173.

[691] T. Voisin, A. Bouvier, and I. M. Chiu, “Neuro-Immune Interactions in Allergic Diseases: Novel Targets for Therapeutics,” International Immunology 29, no. 6 (2017): 247–261.

[692] S. Talbot, R. Abdulnour, P. R. Burkett, et al., “Silencing Nociceptor Neurons Reduces Allergic Airway Inflammation,” Neuron 87, no. 2 (2015): 341–354.

[693] K. G. Margolis and M. D. Gershon, “Neuropeptides and Inflammatory Bowel Disease,” Current Opinion in Gastroenterology 25, no. 6 (2009): 503–511.

[694] A. J. Shepherd, J. E. G. Downing, and J. A. Miyan, “Without Nerves, Immunology Remains Incomplete – In Vivo Veritas,” Immunology 116, no. 2 (2005): 145–163.

[695] J. M. Derocq, M. Ségui, C. Blazy, et al., “Effect of Substance P on Cytokine Production by Human Astrocytic Cells and Blood Mononuclear Cells: Characterization of Novel Tachykinin Receptor Antagonists,” FEBS Letters 399, no. 3 (1996): 321–325.

[696] B. L. Fiebich, S. Schleicher, R. D. Butcher, et al., “The Neuropeptide Substance P Activates p38 Mitogen-Activated Protein Kinase Resulting in IL-6 Expression Independently From NF-Kappa B,” Journal of Immunology (Baltimore, Md) 165, no. 10 (2000): 5606–5611.

[697] I. Karagiannides, E. Kokkotou, M. Tansky, et al., “Induction of Colitis Causes Inflammatory Responses in Fat Depots: Evidence for Substance P Pathways in Human Mesenteric Preadipocytes,” Proceedings of the National Academy of Sciences of the United States of America 103, no. 13 (2006): 5207–5212.

[698] H. Koon, D. Zhao, Y. Zhan, et al., “Substance P-Stimulated Interleukin-8 Expression in Human Colonic Epithelial Cells Involves Protein Kinase Cdelta Activation,” Journal of Pharmacology and Experimental Therapeutics 314, no. 3 (2005): 1393–1400.

[699] K. Lieb, B. L. Fiebich, M. Berger, et al., “The Neuropeptide Substance P Activates Transcription Factor NF-Kappa B and Kappa B-Dependent Gene Expression in Human Astrocytoma Cells,” Journal of Immunology (Baltimore, Md) 159, no. 10 (1997): 4952–4958.

[700] D. Zhao, S. Kuhnt-Moore, H. Zeng, et al., “Substance P-Stimulated Interleukin-8 Expression in Human Colonic Epithelial Cells Involves Rho Family Small GTPases,” Biochemical Journal 368, no. pt. 2 (2002): 665–672.

[701] I. Castagliuolo, O. Morteau, A. C. Keates, et al., “Protective Effects of Neurokinin-1 Receptor During Colitis in Mice: Role of the Epidermal Growth Factor Receptor,” British Journal of Pharmacology 136, no. 2 (2002): 271–279.

[702] Y. Kawahito, H. Sano, M. Kawata, et al., “Local Secretion of Corticotropin-Releasing Hormone by Enterochromaffin Cells in Human Colon,” Gastroenterology 106, no. 4 (1994): 859–865.

[703] M. Saruta, K. Takahashi, T. Suzuki, et al., “Urocortin 1 in Colonic Mucosa in Patients With Ulcerative Colitis,” Journal of Clinical Endocrinology and Metabolism 89, no. 11 (2004): 5352–5361.

[704] E. Gonzalez-Rey, A. Fernandez-Martin, A. Chorny, et al., “Therapeutic Effect of Urocortin and Adrenomedullin in a Murine Model of Crohn's Disease,” Gut 55, no. 6 (2006): 824–832.

[705] J. Gay, E. Kokkotou, M. O'Brien, et al., “Corticotropin-Releasing Hormone Deficiency Is Associated With Reduced Local Inflammation in a Mouse Model of Experimental Colitis,” Endocrinology 149, no. 7 (2008): 3403–3409.

[706] E. Kokkotou, D. Torres, A. C. Moss, et al., “Corticotropin-Releasing Hormone Receptor 2-Deficient Mice Have Reduced Intestinal Inflammatory Responses,” Journal of Immunology (Baltimore, Md) 177, no. 5 (2006): 3355–3361.

[707] J. Zhao and K. P. Karalis, “Regulation of Nuclear Factor-KappaB by Corticotropin-Releasing Hormone in Mouse Thymocytes,” Molecular Endocrinology (Baltimore, Md) 16, no. 11 (2002): 2561–2570.

[708] H. Sashinami, K. Kageyama, T. Suda, et al., “Urocortin 2 Suppresses Host Resistance to Listeria monocytogenes Infection via Up-Regulation of Interleukin-10,” Endocrinology 146, no. 11 (2005): 5003–5011.

[709] C. Tsatsanis, A. Androulidaki, E. Dermitzaki, et al., “Urocortin 1 and Urocortin 2 Induce Macrophage Apoptosis via CRFR2,” FEBS Letters 579, no. 20 (2005): 4259–4264.

[710] R. Carraway and S. E. Leeman, “The Amino Acid Sequence of a Hypothalamic Peptide, Neurotensin,” Journal of Biological Chemistry 250, no. 5 (1975): 1907–1911.

[711] R. M. Navari, “Pharmacological Management of Chemotherapy-Induced Nausea And Vomiting: Focus on Recent Developments,” Drugs 69, no. 5 (2009): 515–533.

[712] R. M. Navari, “Antiemetic Control: Toward a New Standard of Care for Emetogenic Chemotherapy,” Expert Opinion on Pharmacotherapy 10, no. 4 (2009): 629–644.

[713] G. Galy, S. I. Labidi, F. Tissier, et al., “Aprepitant for the Prevention of Cisplatine Induced Nausea and Vomiting: An Observational Study,” Bulletin du Cancer 96, no. 2 (2009): 141–145.

[714] L. Gore, S. Chawla, A. Petrilli, et al., “Aprepitant in Adolescent Patients for Prevention of Chemotherapy-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Tolerability,” Pediatric Blood & Cancer 52, no. 2 (2009): 242–247.

[715] R. M. Navari, “Fosaprepitant: A Neurokinin-1 Receptor Antagonist for the Prevention of Chemotherapy-Induced Nausea and Vomiting,” Expert Review of Anticancer Therapy 8, no. 11 (2008): 1733–1742.

[716] R. Lim, J. M. Morrill, S. G. Prushik, et al., “An FDA Approved Neurokinin-1 Receptor Antagonist Is Effective in Reducing Intraabdominal Adhesions When Administered Intraperitoneally, but not Orally,” Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract 12, no. 10 (2008): 1754–1761.

[717] M. H. Perrin and W. W. Vale, “Corticotropin Releasing Factor Receptors and Their Ligand Family,” Annals of the New York Academy of Sciences 885 (1999): 312–328.

[718] Y. Kawahito, H. Sano, S. Mukai, et al., “Corticotropin Releasing Hormone in Colonic Mucosa in Patients With Ulcerative Colitis,” Gut 37, no. 4 (1995): 544–551.

[719] R. M. Barilla, C. Berard, L. Sun, et al., “Type 2 Cytokines act on Enteric Sensory Neurons to Regulate Neuropeptide-Driven Host Defense,” Science (New York, NY) 389, no. 6757 (2025): 260–267.

[720] F. A. Pinho-Ribeiro, B. Baddal, R. Haarsma, et al., “Blocking Neuronal Signaling to Immune Cells Treats Streptococcal Invasive Infection,” Cell 173, no. 5 (2018): 51083–51097.

[721] Y. Lu, B. Nayer, S. K. Singh, et al., “CGRP Sensory Neurons Promote Tissue Healing via Neutrophils and Macrophages,” Nature 628, no. 8008 (2024): 604–611.

[722] C. Wong and I. M. Chiu, “Neurotransmitter and Neuropeptide Regulation of Gut Immunity,” Current Opinion in Neurobiology 92 (2025): 103036.

[723] Y. Wang, X. Zhang, S. Liu, et al., “Bi-Directional Communication Between Intrinsic Enteric Neurons and ILC2s Inhibits Host Defense Against Helminth Infection,” Immunity 58, no. 2 (2025): 465–480.

[724] W. Wu, B. Feng, J. Liu, et al., “The CGRP/Macrophage Axis Signal Facilitates Inflammation Recovery in the Intestine,” Clinical Immunology (Orlando, Fla) 245 (2022): 109154.

[725] M. Pascual-Mato, G. Gárate, V. González-Quintanilla, et al., “Unravelling the Role of Beta-CGRP in Inflammatory Bowel Disease and Its Potential Role in Gastrointestinal Homeostasis,” BMC Gastroenterology 24, no. 1 (2024): 262.

[726] R. Mallamaci, D. Musarò, M. Greco, et al., “Dopamine- and Grape-Seed-Extract-Loaded Solid Lipid Nanoparticles: Interaction Studies Between Particles and Differentiated SH-SY5Y Neuronal Cell Model of Parkinson's Disease,” Molecules (Basel, Switzerland) 29, no. 8 (2024): 1774.

[727] F. Liang, Q. You, B. Yu, et al., “Neurotransmitter-Mimicking Nanovesicles Facilitate Postoperative Glioblastoma Stem Cell-Specific Treatment for Preventing Tumor Recurrence,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 12, no. 7 (2025): e2409713.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.